qa_id stringlengths 27 27 | qa_group_id stringlengths 28 32 | qa_family stringclasses 3
values | subtask_type stringclasses 7
values | qa_subtype stringclasses 3
values | cluster_id stringclasses 42
values | language stringclasses 1
value | split stringclasses 1
value | question stringlengths 148 1.41k | answer stringlengths 718 10.8k | claim_ids listlengths 0 8 | paper_ids listlengths 1 5 | evidence_span_ids listlengths 0 7 | association_ids listlengths 0 4 | hypothesis_ids listlengths 0 4 | record_json stringlengths 4.37k 33.7k |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
QA:7fba984a2e7f1dca8aceabac | QAG:ab34e2db5f925f46d3c3e633 | provenance_qa | exact_evidence_retrieval | provenance_qa | G008 | en | train | Which exact source passage supports the statement "Similarly, in the TCGA-CRC dataset, the MANTIS score was positively related to increased immunogenicity (such as an increased TMB, NAL, or number of mutations in the DDR pathway; Figure 4B ), the abundances of immune cells (such as M1 macrophages, neutrophils, activate... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:ba0ca81984e65890816ed98a","quotes":["Similarly, in the TCGA-CRC dataset, the MANTIS score was positively related ... | [
"CLM:ba0ca81984e65890816ed98a",
"CLM:64822c34f03e6ab9a02ee6f5"
] | [
"PMCID:PMC7435056"
] | [
"SPAN:c32be2aee32544c8ce3ab7c1"
] | [] | [] | {"qa_id":"QA:7fba984a2e7f1dca8aceabac","qa_group_id":"QAG:ab34e2db5f925f46d3c3e633","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G008","question":"Which exact source passage supports the statement \"Similarly, in the TCGA-CRC dataset, the MANTIS score was positivel... |
QA:81aac5f86863acaafe7cbcf6 | QAG:7a71acf75d74a29064e7b5fb | provenance_qa | exact_evidence_retrieval | provenance_qa | G008 | en | train | Which exact source passage supports the statement "In addition, a large number of antigen processing and presentation-related genes exhibit increased expression in MSI-H CRC and COAD, which play an important role in the recruitment of effector T cells and lymphocytes to neoantigen-expressing tumor cells and thus stimul... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:ced78b0a7a6b088b2541b7d1","quotes":["In addition, a large number of antigen processing and presentation-related g... | [
"CLM:ced78b0a7a6b088b2541b7d1",
"CLM:76b5c39658e904fe9e6f7dd7"
] | [
"PMCID:PMC7435056"
] | [
"SPAN:f530086db36cba2a2a236cee"
] | [] | [] | {"qa_id":"QA:81aac5f86863acaafe7cbcf6","qa_group_id":"QAG:7a71acf75d74a29064e7b5fb","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G008","question":"Which exact source passage supports the statement \"In addition, a large number of antigen processing and presentation... |
QA:81e3026ead9b85086d534949 | QAG:5939db27ea8c0e6c14530174 | provenance_qa | exact_evidence_retrieval | provenance_qa | G008 | en | train | Which exact source passage supports the statement "43 Taken together, the effects of DNMTi promote radiotherapy promoted antitumor immunity by not only upregulating cancer immunogenicity but also inducing the IFNβ immune response to enhance anti-PD-L1 immunotherapy in colorectal cancer"? Return the original wording wit... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:b0571dab7c3bbcd5ae8acc97","quotes":["43 Taken together, the effects of DNMTi promote radiotherapy-induced antitum... | [
"CLM:b0571dab7c3bbcd5ae8acc97",
"CLM:64822c34f03e6ab9a02ee6f5"
] | [
"PMCID:PMC10813565"
] | [
"SPAN:34a4941ae985b98d2dd1fad9"
] | [] | [] | {"qa_id":"QA:81e3026ead9b85086d534949","qa_group_id":"QAG:5939db27ea8c0e6c14530174","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G008","question":"Which exact source passage supports the statement \"43 Taken together, the effects of DNMTi promote radiotherapy promo... |
QA:82a2ea3de2920bf78e401e21 | QAG:54dedfee9433094c98d018d9 | provenance_qa | exact_evidence_retrieval | provenance_qa | G008 | en | train | Which exact source passage supports the statement "In contrast to previous reports showing that autophagy inhibition in highly transformed cell lines or primary intestinal epithelial cells sensitized them to TNF- or IFNγ promoted cytotoxicity 22 , 46 , IFNγ or TNF alone were unable to induce CRC organoid death in vitro... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:7adf34d89e2caec173029dfb","quotes":["In contrast to previous reports showing that autophagy inhibition in highly ... | [
"CLM:7adf34d89e2caec173029dfb",
"CLM:64822c34f03e6ab9a02ee6f5"
] | [
"PMCID:PMC10517947"
] | [
"SPAN:7bc755d300deb4aaf987e51e"
] | [] | [] | {"qa_id":"QA:82a2ea3de2920bf78e401e21","qa_group_id":"QAG:54dedfee9433094c98d018d9","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G008","question":"Which exact source passage supports the statement \"In contrast to previous reports showing that autophagy inhibition ... |
QA:82d9d0261d7feb96b2770c45 | QAG:1002d86d9bcb03e9f9dbbcab | provenance_qa | exact_evidence_retrieval | provenance_qa | G008 | en | train | Which exact source passage supports the statement "Here, we demonstrate that high tumor expression of the core autophagy gene ATG16L1 was associated with poor clinical response to anti-PD-L1 therapy in KRAS-mutant tumors from IMblaze370 (NCT02788279), a large phase III clinical trial of atezolizumab (anti-PD-L1) in adv... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification","cross_paper_provenance"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:b0532f1ff4d34c3253c6c43b","quotes":["Here, we demonstrate that high tumor expression of ... | [
"CLM:b0532f1ff4d34c3253c6c43b",
"CLM:76b5c39658e904fe9e6f7dd7",
"CLM:71c873fe5dde30cad48ecf08"
] | [
"PMCID:PMC10517947",
"PMCID:PMC10813565"
] | [
"SPAN:09950cd470fa50327d450eab",
"SPAN:b58976d6e10e6df790c4c1b9"
] | [
"ASC2:e0eb5dc582760a839490b6ca"
] | [
"HYP:DCH:159b056e0522886362299c75"
] | {"qa_id":"QA:82d9d0261d7feb96b2770c45","qa_group_id":"QAG:1002d86d9bcb03e9f9dbbcab","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G008","question":"Which exact source passage supports the statement \"Here, we demonstrate that high tumor expression of the core autoph... |
QA:8369758430bfa4a5c83579a7 | QAG:d02cc46aa22c5418c913ace8 | provenance_qa | exact_evidence_retrieval | provenance_qa | G008 | en | train | Which exact source passage supports the statement "Although high expression of T and B cell signatures predicted improved OS in many cancer types, there was no statistically significant associ- ation observed with CRC"? Return the original wording with paper, Claim, and Evidence Span references.
Integrated provenance ... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:9b0ddc753048c00f8167c36a","quotes":["Although\nhigh expression of T and B cell signatures predicted improved OS\n... | [
"CLM:9b0ddc753048c00f8167c36a",
"CLM:64822c34f03e6ab9a02ee6f5"
] | [
"PMCID:PMC6763253"
] | [
"SPAN:b101d9a1d5a9cda44a009cf6"
] | [] | [] | {"qa_id":"QA:8369758430bfa4a5c83579a7","qa_group_id":"QAG:d02cc46aa22c5418c913ace8","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G008","question":"Which exact source passage supports the statement \"Although high expression of T and B cell signatures predicted impr... |
QA:84892fd4d7766eb808407b43 | QAG:e20eedd1631755faf7981b26 | provenance_qa | exact_evidence_retrieval | provenance_qa | G008 | en | train | Which exact source passage supports the statement "2d ), loss of host IFNγ increased liver colonization by Atg16l1 KO CRC organoids as shown by BLI quantification (Fig. 2g, h ; Supplementary Fig. 8d ; WT host vs. IFNγ KO host), macroscopic tumor nodule count (Supplementary Fig. 8e ), and histologic examination (Supplem... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:0182949cbe2fbec4e70ab916","quotes":["Compared to WT control hosts (Fig. 2d ), loss of host IFNγ significantly inc... | [
"CLM:0182949cbe2fbec4e70ab916",
"CLM:64822c34f03e6ab9a02ee6f5"
] | [
"PMCID:PMC10517947"
] | [
"SPAN:b3806c90296c5f184a8106d0"
] | [] | [] | {"qa_id":"QA:84892fd4d7766eb808407b43","qa_group_id":"QAG:e20eedd1631755faf7981b26","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G008","question":"Which exact source passage supports the statement \"2d ), loss of host IFNγ increased liver colonization by Atg16l1 KO... |
QA:84bc5fe87ea46a17b3aca764 | QAG:283166a50fcc0c137b57a447 | provenance_qa | exact_evidence_retrieval | provenance_qa | G008 | en | train | Which exact source passage supports the statement "Microsatellite status of primary colorectal cancer predicted the incidence of postoperative colorectal neoplasms. Anticancer Res"? Return the original wording with paper, Claim, and Evidence Span references.
Integrated provenance requirements: return the exact support... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:74b1a06bb94d5ff4fe449d9c","quotes":["Microsatellite status of primary colorectal cancer predicts the incidence of... | [
"CLM:74b1a06bb94d5ff4fe449d9c",
"CLM:64822c34f03e6ab9a02ee6f5"
] | [
"PMCID:PMC7212380"
] | [
"SPAN:61f87131cf941229c6853ce8"
] | [] | [] | {"qa_id":"QA:84bc5fe87ea46a17b3aca764","qa_group_id":"QAG:283166a50fcc0c137b57a447","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G008","question":"Which exact source passage supports the statement \"Microsatellite status of primary colorectal cancer predicted the i... |
QA:853876aa4dd4dee9bb45f469 | QAG:0da6dbf47e7159a4d42d302b | provenance_qa | exact_evidence_retrieval | provenance_qa | G008 | en | train | Which exact source passage supports the statement "ATG16L1 deficiency enhances programmed cell death of colon cancer organoids promoted by IFN-γ and TNF, thus increasing their sensitivity to host immunity"? Return the original wording with paper, Claim, and Evidence Span references.
Integrated provenance requirements:... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:317059fc49f5a3003aa3a1cc","quotes":["ATG16L1 deficiency enhances programmed cell death of colon cancer organoids ... | [
"CLM:317059fc49f5a3003aa3a1cc",
"CLM:76b5c39658e904fe9e6f7dd7"
] | [
"PMCID:PMC10517947"
] | [
"SPAN:224f7c99ee5967bbcd1dc02a"
] | [] | [] | {"qa_id":"QA:853876aa4dd4dee9bb45f469","qa_group_id":"QAG:0da6dbf47e7159a4d42d302b","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G008","question":"Which exact source passage supports the statement \"ATG16L1 deficiency enhances programmed cell death of colon cancer ... |
QA:875ee9535f8aa7bafb171d26 | QAG:0bae0aeee6e986bf779872da | provenance_qa | exact_evidence_retrieval | provenance_qa | G008 | en | train | Which exact source passage supports the statement "Antitumour immunity invoked by hepatic arterial infusion of first-line oxaliplatin predicted durable colorectal cancer control after liver metastasis ablation: 8-12 years of follow-up"? Return the original wording with paper, Claim, and Evidence Span references.
Integ... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:c0775fc9c79fc29f804419bb","quotes":["30. Abrahamsson H, Jensen BV, Berven LL, Nielsen DL, Saltyte Benth J, Johans... | [
"CLM:c0775fc9c79fc29f804419bb",
"CLM:64822c34f03e6ab9a02ee6f5"
] | [
"PMCID:PMC7689210"
] | [
"SPAN:cf1372648bf70154b6bdc41b"
] | [] | [] | {"qa_id":"QA:875ee9535f8aa7bafb171d26","qa_group_id":"QAG:0bae0aeee6e986bf779872da","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G008","question":"Which exact source passage supports the statement \"Antitumour immunity invoked by hepatic arterial infusion of first-... |
QA:88f6237283ff376219d79e90 | QAG:76f487da7d8fe9524f166041 | provenance_qa | exact_evidence_retrieval | provenance_qa | G008 | en | train | Which exact source passage supports the statement "Because the CMS4 subset was associated with angiogenesis and inflammation , we assessed the correlation between OLFML3 and angiogenic factor expression in a CRC RNA dataset (GO: 0001525)"? Return the original wording with paper, Claim, and Evidence Span references.
In... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:3b393a421a6879629754de5f","quotes":["Because the CMS4 subset is associated with angiogenesis and inflammation [ 2... | [
"CLM:3b393a421a6879629754de5f",
"CLM:64822c34f03e6ab9a02ee6f5"
] | [
"PMCID:PMC8464773"
] | [
"SPAN:887ebc49560d53bde1cc2502"
] | [] | [] | {"qa_id":"QA:88f6237283ff376219d79e90","qa_group_id":"QAG:76f487da7d8fe9524f166041","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G008","question":"Which exact source passage supports the statement \"Because the CMS4 subset was associated with angiogenesis and infla... |
QA:8bf5e9ed671269147377e61f | QAG:99f11cf9ecb13e586ceda522 | provenance_qa | paper_evidence_availability | provenance_qa | G008 | en | train | Does the current traceable evidence dataset contain a usable Claim and exact source span for paper PMCID:PMC5665850? Explicitly abstain if it does not.
Integrated provenance requirements: report evidence availability or insufficiency without inventing missing full text. Keep each subtask answer separately identifiable... | {"answer_type":"integrated_provenance","embedded_answer_types":["paper_evidence_availability"],"exact_evidence_retrieval":null,"limited_evidence_retrieval":null,"paper_evidence_availability":{"answer_type":"explicit_evidence_abstention","paper_id":"PMCID:PMC5665850","verdict":"no_released_traceable_claim","reason":"No ... | [] | [
"PMCID:PMC5665850"
] | [] | [] | [] | {"qa_id":"QA:8bf5e9ed671269147377e61f","qa_group_id":"QAG:99f11cf9ecb13e586ceda522","qa_family":"provenance_qa","subtask_type":"paper_evidence_availability","language":"en","cluster_id":"G008","question":"Does the current traceable evidence dataset contain a usable Claim and exact source span for paper PMCID:PMC5665850... |
QA:8c8fc1617ba51653974f478f | QAG:de0cfb7edd30bfb0d19942b1 | provenance_qa | exact_evidence_retrieval | provenance_qa | G008 | en | train | Which exact source passage supports the statement "Moreover, two loci (cg15837913 and cg19724470) targeting CpGs within the upstream CpG-island located in the CD274 promoter was associated with survival outcome in several malignancies, including colorectal cancer"? Return the original wording with paper, Claim, and Evi... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:1b908f3c63cf5a14f5aa2f96","quotes":["Moreover, two loci (cg15837913 and cg19724470) targeting CpGs within the ups... | [
"CLM:1b908f3c63cf5a14f5aa2f96",
"CLM:64822c34f03e6ab9a02ee6f5"
] | [
"PMCID:PMC10813565"
] | [
"SPAN:ac670f7ad95224d68250fef4"
] | [] | [] | {"qa_id":"QA:8c8fc1617ba51653974f478f","qa_group_id":"QAG:de0cfb7edd30bfb0d19942b1","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G008","question":"Which exact source passage supports the statement \"Moreover, two loci (cg15837913 and cg19724470) targeting CpGs with... |
QA:8d628beb1ffc92e2a8902752 | QAG:ddfc4dc0aba1d3953bc068a0 | provenance_qa | exact_evidence_retrieval | provenance_qa | G008 | en | train | Which exact source passage supports the statement "As expected, the MSI-H CRC group was associated with a better prognosis for immunotherapy than was the MSS/MSI-L tumor mutational burden-low (TMB-L) group ( P = 0.002; Figure 1C )"? Return the original wording with paper, Claim, and Evidence Span references.
Integrate... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:6015d1f93d2fbee96dcd97dd","quotes":["As expected, the MSI-H CRC group was associated with a better prognosis for ... | [
"CLM:6015d1f93d2fbee96dcd97dd",
"CLM:76b5c39658e904fe9e6f7dd7"
] | [
"PMCID:PMC7435056"
] | [
"SPAN:22190dbde2c0491e73818be9"
] | [] | [] | {"qa_id":"QA:8d628beb1ffc92e2a8902752","qa_group_id":"QAG:ddfc4dc0aba1d3953bc068a0","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G008","question":"Which exact source passage supports the statement \"As expected, the MSI-H CRC group was associated with a better prog... |
QA:8fa094deb1451f23f08f78a7 | QAG:2ff48de8fb32a6644679f9c8 | provenance_qa | exact_evidence_retrieval | provenance_qa | G008 | en | train | Which exact source passage supports the statement "Measurements of number of metastases (A) and tumor volume (B) for patients with liver-limited metastatic colorectal cancer who received standard-of-care (SOC) observation or BA (trial cohort)"? Return the original wording with paper, Claim, and Evidence Span references... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:1e4acbcb796b4baf16cdb84f","quotes":["Measurements of number of metastases (A) and tumor volume (B) for patients w... | [
"CLM:1e4acbcb796b4baf16cdb84f",
"CLM:64822c34f03e6ab9a02ee6f5"
] | [
"PMCID:PMC9648419"
] | [
"SPAN:63836713afe8ff69053c518d"
] | [] | [] | {"qa_id":"QA:8fa094deb1451f23f08f78a7","qa_group_id":"QAG:2ff48de8fb32a6644679f9c8","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G008","question":"Which exact source passage supports the statement \"Measurements of number of metastases (A) and tumor volume (B) for ... |
QA:901f13c2f62b6da22441dac7 | QAG:d7043fb72fa5100290681d16 | provenance_qa | exact_evidence_retrieval | provenance_qa | G008 | en | train | Which exact source passage supports the statement "Indeed, in patients with colorectal cancer who undergo complete surgical resection, the detection of ctDNA was associated with inevitable disease recurrence and therefore serves as a surrogate for the existence of persistent minimal residual (micrometastatic) disease"?... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:13ab1a21621687d03c2a4376","quotes":["Indeed, in patients with colorectal cancer who undergo complete surgical res... | [
"CLM:13ab1a21621687d03c2a4376",
"CLM:64822c34f03e6ab9a02ee6f5"
] | [
"PMCID:PMC9648419"
] | [
"SPAN:ebb86234894e0ad0ff02a233"
] | [] | [] | {"qa_id":"QA:901f13c2f62b6da22441dac7","qa_group_id":"QAG:d7043fb72fa5100290681d16","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G008","question":"Which exact source passage supports the statement \"Indeed, in patients with colorectal cancer who undergo complete su... |
QA:9359781dd769db21233b9a16 | QAG:5ca9bb2f7ff171606372b53c | provenance_qa | exact_evidence_retrieval | provenance_qa | G008 | en | train | Which exact source passage supports the statement "Patients who had received prior treatment with a PD-1 or PD-L1 inhibitor were not eligible for inclusion in cohorts 1–6. Patients who had received prior PD-1 or PD-L1 therapy were eligible for inclusion in cohort 7A if it was their most recent/current line of therapy a... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification","cross_paper_provenance"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:28ab17ada0f4f50211ffb2cd","quotes":["Patients who had received prior treatment with a PD... | [
"CLM:28ab17ada0f4f50211ffb2cd",
"CLM:3cc797726363fb29928626a6"
] | [
"PMCID:PMC10151977",
"PMCID:PMC5823560"
] | [
"SPAN:28060c64c1a704e1bf44cd69",
"SPAN:52019a971ff49ae810a0a044",
"SPAN:bf31c33b34baabc97df027de"
] | [
"ASC2:b8eb3922d82ab279770034f9"
] | [
"HYP:DCH:d60540d71a0839ba17ba0fbd"
] | {"qa_id":"QA:9359781dd769db21233b9a16","qa_group_id":"QAG:5ca9bb2f7ff171606372b53c","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G008","question":"Which exact source passage supports the statement \"Patients who had received prior treatment with a PD-1 or PD-L1 inh... |
QA:945639ece12a1dfcdd5efe0d | QAG:c0ac230a2e15af7e8a757a65 | provenance_qa | exact_evidence_retrieval | provenance_qa | G008 | en | train | Which exact source passage supports the statement "F5446 inhibited H3K9me3, thereby upregulating expression of these effectors in tumor-infiltrating CTLs and suppressing colon carcinoma growth in a CD8 + CTL-dependent manner in vivo Our data indicate that SUV39H1 represses CTL effector gene expression and, in doing so,... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:9ae1604f7e08643abd95e866","quotes":["F5446 inhibited H3K9me3, thereby upregulating expression of these effectors ... | [
"CLM:9ae1604f7e08643abd95e866",
"CLM:64822c34f03e6ab9a02ee6f5"
] | [
"PMCID:PMC6397681"
] | [
"SPAN:7c179738fc44f21ec2d04790"
] | [] | [] | {"qa_id":"QA:945639ece12a1dfcdd5efe0d","qa_group_id":"QAG:c0ac230a2e15af7e8a757a65","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G008","question":"Which exact source passage supports the statement \"F5446 inhibited H3K9me3, thereby upregulating expression of these ... |
QA:95ecd7289d54f38b8150a4c9 | QAG:c85cb9841e3751295020242c | provenance_qa | exact_evidence_retrieval | provenance_qa | G008 | en | train | Which exact source passage supports the statement "Prompted by the observation that increased ATG16L1 expression associates with poor outcome in late-stage CRC, we functionally evaluated its role in CRC progression"? Return the original wording with paper, Claim, and Evidence Span references.
Integrated provenance req... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:a1f075196a7c49e9d84a6511","quotes":["Prompted by the observation that elevated ATG16L1 expression associates with... | [
"CLM:a1f075196a7c49e9d84a6511",
"CLM:76b5c39658e904fe9e6f7dd7"
] | [
"PMCID:PMC10517947"
] | [
"SPAN:f16c0616bdea37a8bbd06e6d"
] | [] | [] | {"qa_id":"QA:95ecd7289d54f38b8150a4c9","qa_group_id":"QAG:c85cb9841e3751295020242c","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G008","question":"Which exact source passage supports the statement \"Prompted by the observation that increased ATG16L1 expression asso... |
QA:95eef15726337da22acbf001 | QAG:312e11e5367604532d5d00af | provenance_qa | paper_evidence_availability | provenance_qa | G008 | en | train | Does the current traceable evidence dataset contain a usable Claim and exact source span for paper PMCID:PMC8657606? Explicitly abstain if it does not.
Integrated provenance requirements: report evidence availability or insufficiency without inventing missing full text. Keep each subtask answer separately identifiable... | {"answer_type":"integrated_provenance","embedded_answer_types":["paper_evidence_availability"],"exact_evidence_retrieval":null,"limited_evidence_retrieval":null,"paper_evidence_availability":{"answer_type":"explicit_evidence_abstention","paper_id":"PMCID:PMC8657606","verdict":"no_released_traceable_claim","reason":"No ... | [] | [
"PMCID:PMC8657606"
] | [] | [] | [] | {"qa_id":"QA:95eef15726337da22acbf001","qa_group_id":"QAG:312e11e5367604532d5d00af","qa_family":"provenance_qa","subtask_type":"paper_evidence_availability","language":"en","cluster_id":"G008","question":"Does the current traceable evidence dataset contain a usable Claim and exact source span for paper PMCID:PMC8657606... |
QA:97361bab09ff30aa62009d06 | QAG:7a1bb1f5e29888379fa64e33 | provenance_qa | exact_evidence_retrieval | provenance_qa | G008 | en | train | Which exact source passage supports the statement "In total, 19 patients with refractory advanced CRC (12 male and 7 female) with MSS or pMMR were enrolled with a median age was 52 years"? Return the original wording with paper, Claim, and Evidence Span references.
Integrated provenance requirements: return the exact ... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:ab159844d9da42b53dfb45cb","quotes":["In total, 19 patients with refractory advanced CRC (12 male and 7 female) wi... | [
"CLM:ab159844d9da42b53dfb45cb",
"CLM:64822c34f03e6ab9a02ee6f5"
] | [
"PMCID:PMC10186513"
] | [
"SPAN:0a9418327875110019304784"
] | [] | [] | {"qa_id":"QA:97361bab09ff30aa62009d06","qa_group_id":"QAG:7a1bb1f5e29888379fa64e33","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G008","question":"Which exact source passage supports the statement \"In total, 19 patients with refractory advanced CRC (12 male and 7 ... |
QA:97dfc4c172901bf396118fda | QAG:7859fa7a67e86f8eed7539af | provenance_qa | exact_evidence_retrieval | provenance_qa | G008 | en | train | Which exact source passage supports the statement "Collectively, these data suggest that loss of Atg16l1 led to a reduction of the goblet, Paneth, stem cell and proliferative pools in CRC organoids, potentially restraining tumor growth"? Return the original wording with paper, Claim, and Evidence Span references.
Inte... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:84ad4f91f8bc73cd1217db69","quotes":["Collectively, these data suggest that loss of Atg16l1 leads to a reduction o... | [
"CLM:84ad4f91f8bc73cd1217db69",
"CLM:64822c34f03e6ab9a02ee6f5"
] | [
"PMCID:PMC10517947"
] | [
"SPAN:8379bb1cb9914ee7050dd9d0"
] | [] | [] | {"qa_id":"QA:97dfc4c172901bf396118fda","qa_group_id":"QAG:7859fa7a67e86f8eed7539af","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G008","question":"Which exact source passage supports the statement \"Collectively, these data suggest that loss of Atg16l1 led to a red... |
QA:980a83925511ddb5ddce8290 | QAG:13686419ee3765bdc14caa24 | provenance_qa | exact_evidence_retrieval | provenance_qa | G008 | en | train | Which exact source passage supports the statement "FIGURE 2 MSI-H CRC was associated with enhanced tumor immunogenicity, enriched immune cells and enhanced immune scores"? Return the original wording with paper, Claim, and Evidence Span references.
Integrated provenance requirements: return the exact supporting passag... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:bc717cce80e3019a057d744f","quotes":["FIGURE 2 MSI-H CRC was associated with enhanced tumor immunogenicity, enrich... | [
"CLM:bc717cce80e3019a057d744f",
"CLM:64822c34f03e6ab9a02ee6f5"
] | [
"PMCID:PMC7435056"
] | [
"SPAN:c10406c8ca92adfaff9800c1"
] | [] | [] | {"qa_id":"QA:980a83925511ddb5ddce8290","qa_group_id":"QAG:13686419ee3765bdc14caa24","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G008","question":"Which exact source passage supports the statement \"FIGURE 2 MSI-H CRC was associated with enhanced tumor immunogenici... |
QA:98a3415a8fdb8fe7fd388108 | QAG:b67acc3d43f54050b40da666 | provenance_qa | exact_evidence_retrieval | provenance_qa | G008 | en | train | Which exact source passage supports the statement "The number of genetic mutations involved in several important pathways in the DDR system was higher than the MSI-H group than in the MSS/MSI-L group for both CRC patients and CRC cell lines (all P < 0.0001; Figure 2K )"? Return the original wording with paper, Claim, a... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:84e118ff019e16d77ea1d8c5","quotes":["The number of genetic mutations involved in several important pathways in th... | [
"CLM:84e118ff019e16d77ea1d8c5",
"CLM:64822c34f03e6ab9a02ee6f5"
] | [
"PMCID:PMC7435056"
] | [
"SPAN:4d6d3d64d9c36fc285744669"
] | [] | [] | {"qa_id":"QA:98a3415a8fdb8fe7fd388108","qa_group_id":"QAG:b67acc3d43f54050b40da666","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G008","question":"Which exact source passage supports the statement \"The number of genetic mutations involved in several important path... |
QA:9bdf5619b75ba323e431527e | QAG:7553410e39580f8adad9337f | provenance_qa | paper_evidence_availability | provenance_qa | G008 | en | train | Does the current traceable evidence dataset contain a usable Claim and exact source span for paper PMCID:PMC7514069? Explicitly abstain if it does not.
Integrated provenance requirements: report evidence availability or insufficiency without inventing missing full text. Keep each subtask answer separately identifiable... | {"answer_type":"integrated_provenance","embedded_answer_types":["paper_evidence_availability"],"exact_evidence_retrieval":null,"limited_evidence_retrieval":null,"paper_evidence_availability":{"answer_type":"explicit_evidence_abstention","paper_id":"PMCID:PMC7514069","verdict":"no_released_traceable_claim","reason":"No ... | [] | [
"PMCID:PMC7514069"
] | [] | [] | [] | {"qa_id":"QA:9bdf5619b75ba323e431527e","qa_group_id":"QAG:7553410e39580f8adad9337f","qa_family":"provenance_qa","subtask_type":"paper_evidence_availability","language":"en","cluster_id":"G008","question":"Does the current traceable evidence dataset contain a usable Claim and exact source span for paper PMCID:PMC7514069... |
QA:9be65629b1e5b47eafabc245 | QAG:8b47d68e307790b1cb34d6e8 | provenance_qa | exact_evidence_retrieval | provenance_qa | G008 | en | train | Which exact source passage supports the statement "5 Atg16l1 loss sensitizes CRC organoids to TNF + IFNγ promoted cell death. a GSEA using MSigDB IFNγ response hallmark gene set for differential expression between Atg16l1 KO ( n = 2) and WT ( n = 2) CRC organoids treated (in vitro bulk RNA-seq data) with p -value = 4.7... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:d39c5ce1b689e2679eb5075b","quotes":["Fig. 5 Atg16l1 loss sensitizes CRC organoids to TNF + IFNγ-induced cell deat... | [
"CLM:d39c5ce1b689e2679eb5075b",
"CLM:64822c34f03e6ab9a02ee6f5"
] | [
"PMCID:PMC10517947"
] | [
"SPAN:730dfccea9717bc572afb42d"
] | [] | [] | {"qa_id":"QA:9be65629b1e5b47eafabc245","qa_group_id":"QAG:8b47d68e307790b1cb34d6e8","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G008","question":"Which exact source passage supports the statement \"5 Atg16l1 loss sensitizes CRC organoids to TNF + IFNγ promoted cel... |
QA:9ca0fca3407cb5d33cb3d7b2 | QAG:6cad7161b2fdd3ac9b6fc766 | provenance_qa | exact_evidence_retrieval | provenance_qa | G008 | en | train | Which exact source passage supports the statement "2017 ), while approximately 10–15% of CRC tumors was associated with MSI ( Boland and Goel, 2010 )"? Return the original wording with paper, Claim, and Evidence Span references.
Integrated provenance requirements: return the exact supporting passage with paper, Claim,... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification","cross_paper_provenance"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:2560bc1f8e2c9438c608e023","quotes":["Studies have shown that immune CPI monotherapy, inc... | [
"CLM:2560bc1f8e2c9438c608e023",
"CLM:64822c34f03e6ab9a02ee6f5",
"CLM:b2d474f7680804de4fef4716",
"CLM:3cc797726363fb29928626a6"
] | [
"PMCID:PMC7212380",
"PMCID:PMC8114827",
"PMCID:PMC5823560"
] | [
"SPAN:6dc39dfa43d2ca1c1df4235b",
"SPAN:242f3d146fd0461b1fda0288",
"SPAN:bf31c33b34baabc97df027de"
] | [
"ASC2:56ef709b8fb7b2450854759b",
"ASC2:2a028abb8b5927a8b08d5b46"
] | [
"HYP:DCH:5c5c73f97989d8f1ba1b343b"
] | {"qa_id":"QA:9ca0fca3407cb5d33cb3d7b2","qa_group_id":"QAG:6cad7161b2fdd3ac9b6fc766","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G008","question":"Which exact source passage supports the statement \"2017 ), while approximately 10–15% of CRC tumors was associated wi... |
QA:9ef6868da62f1c85eef7b7a2 | QAG:0866ae3c3c929210ea128c5a | provenance_qa | exact_evidence_retrieval | provenance_qa | G008 | en | train | Which exact source passage supports the statement "Immune checkpoint inhibitor (ICI) therapy has achieved impressive success in deficient mismatch repair (dMMR)/microsatellite instability-high (MSI-H) colorectal cancer (CRC)"? Return the original wording with paper, Claim, and Evidence Span references.
Integrated prov... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:d68b7f9399d7763d6898c21f","quotes":["Immune checkpoint inhibitor (ICI) therapy has achieved impressive success in... | [
"CLM:d68b7f9399d7763d6898c21f",
"CLM:76b5c39658e904fe9e6f7dd7"
] | [
"PMCID:PMC9720302"
] | [
"SPAN:780e8245c11645d36e09470a"
] | [] | [] | {"qa_id":"QA:9ef6868da62f1c85eef7b7a2","qa_group_id":"QAG:0866ae3c3c929210ea128c5a","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G008","question":"Which exact source passage supports the statement \"Immune checkpoint inhibitor (ICI) therapy has achieved impressive ... |
QA:9f4815477918be5a44ec745e | QAG:d48fca61e5f8dab7934a211c | provenance_qa | exact_evidence_retrieval | provenance_qa | G008 | en | train | Which exact source passage supports the statement "It is well known that PD-L1 expression promoted by IFNγ was mainly controlled by the JAK-STAT, MAPK or PI3K-AKT pathways"? Return the original wording with paper, Claim, and Evidence Span references.
Integrated provenance requirements: return the exact supporting pass... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:06c961f443b6137d9626b304","quotes":["It is well known that PD-L1 expression stimulated by IFNγ was mainly control... | [
"CLM:06c961f443b6137d9626b304",
"CLM:64822c34f03e6ab9a02ee6f5"
] | [
"PMCID:PMC8114827"
] | [
"SPAN:9cd51b0c532da98bb633665d",
"SPAN:ae871f163b6977be6f11fd6b"
] | [] | [] | {"qa_id":"QA:9f4815477918be5a44ec745e","qa_group_id":"QAG:d48fca61e5f8dab7934a211c","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G008","question":"Which exact source passage supports the statement \"It is well known that PD-L1 expression promoted by IFNγ was mainly... |
QA:a4fe4ae3acf62c2a3beb64ce | QAG:73af4a8412580508030abb8b | provenance_qa | exact_evidence_retrieval | provenance_qa | G008 | en | train | Which exact source passage supports the statement "We focused on colorectal cancer (CRC), as increased expression of OLFML3 mRNA correlated with shorter relapse-free survival, higher tumor grade, and angiogenic microsatellite stable consensus molecular subtype 4 (CMS4)"? Return the original wording with paper, Claim, a... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:00cdbcdd53550cfd7c8ac493","quotes":["We focused on colorectal cancer (CRC), as elevated expression of OLFML3 mRNA... | [
"CLM:00cdbcdd53550cfd7c8ac493",
"CLM:64822c34f03e6ab9a02ee6f5"
] | [
"PMCID:PMC8464773"
] | [
"SPAN:a7f2ba05b0eb0b66636452f1"
] | [] | [] | {"qa_id":"QA:a4fe4ae3acf62c2a3beb64ce","qa_group_id":"QAG:73af4a8412580508030abb8b","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G008","question":"Which exact source passage supports the statement \"We focused on colorectal cancer (CRC), as increased expression of ... |
QA:a556e649fbb293033e51df68 | QAG:acf7294a796136030df25c76 | provenance_qa | exact_evidence_retrieval | provenance_qa | G008 | en | train | Which exact source passage supports the statement "In cells co-cultured with TNFα to mimic an inflammatory tumor microenvironment, tolinapant promoted caspase-8-dependent apoptosis in colorectal cancer cell line models; however, the extent of apoptosis was limited because of inhibition by the caspase-8 paralogs FLIP an... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:72f90835d2d023dffb2c2ffa","quotes":["In cells co-cultured with TNFα to mimic an inflammatory tumor microenvironme... | [
"CLM:72f90835d2d023dffb2c2ffa",
"CLM:64822c34f03e6ab9a02ee6f5"
] | [
"PMCID:PMC7611622"
] | [
"SPAN:b8f746d9a3fd6c9da1312352"
] | [] | [] | {"qa_id":"QA:a556e649fbb293033e51df68","qa_group_id":"QAG:acf7294a796136030df25c76","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G008","question":"Which exact source passage supports the statement \"In cells co-cultured with TNFα to mimic an inflammatory tumor micr... |
QA:a640fcf33443dd9aff382581 | QAG:6ce0640e9d6809971a6b6a11 | provenance_qa | exact_evidence_retrieval | provenance_qa | G008 | en | train | Which exact source passage supports the statement "In TCGA cohort, epigenetic-related gene mutations was associated with an increased incidence of TMB in MSS-CRC (median mutation rate of 4.76/mb vs. 4.99/mb in Wt and Mut cases, respectively; p = 7.4e-05; Figure 2A )"? Return the original wording with paper, Claim, and ... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:ab4e6a06db1a39de21d3a612","quotes":["In TCGA cohort, epigenetic-related gene mutations were associated with an in... | [
"CLM:ab4e6a06db1a39de21d3a612",
"CLM:76b5c39658e904fe9e6f7dd7"
] | [
"PMCID:PMC9720302"
] | [
"SPAN:86370e69a96124179715479f"
] | [] | [] | {"qa_id":"QA:a640fcf33443dd9aff382581","qa_group_id":"QAG:6ce0640e9d6809971a6b6a11","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G008","question":"Which exact source passage supports the statement \"In TCGA cohort, epigenetic-related gene mutations was associated w... |
QA:a86559ceece3a6c96c5f3698 | QAG:acf0c00d92bb17b5a7a1113c | provenance_qa | exact_evidence_retrieval | provenance_qa | G008 | en | train | Which exact source passage supports the statement "The expression of the H3K9me3-specific histone methyltransferase SUV39H1 was increased in human colon carcinoma compared with normal colon tissues"? Return the original wording with paper, Claim, and Evidence Span references.
Integrated provenance requirements: return... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:1b4d82701dcf1c96904702e7","quotes":["The expression of the H3K9me3-specific histone methyltransferase SUV39H1 was... | [
"CLM:1b4d82701dcf1c96904702e7",
"CLM:64822c34f03e6ab9a02ee6f5"
] | [
"PMCID:PMC6397681"
] | [
"SPAN:b03d33338c40af9daf2d1523"
] | [] | [] | {"qa_id":"QA:a86559ceece3a6c96c5f3698","qa_group_id":"QAG:acf0c00d92bb17b5a7a1113c","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G008","question":"Which exact source passage supports the statement \"The expression of the H3K9me3-specific histone methyltransferase S... |
QA:aa599e876612d23128bf3e0e | QAG:af3e7ef6aec48eae0770a997 | provenance_qa | exact_evidence_retrieval | provenance_qa | G008 | en | train | Which exact source passage supports the statement "The multivariate Cox proportional hazards regression analysis results showed that liver metastases, ALP level, FIB level, and changes in ALP level after treatment was associated with PFS in fruquintinib coupled with PD-1 inhibitors in MSS/pMMR CRC (P<0.05, Table 4 )"? ... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:d15bf0ba6bd81d66aab07aef","quotes":["The multivariate Cox proportional hazards regression analysis results showed... | [
"CLM:d15bf0ba6bd81d66aab07aef",
"CLM:64822c34f03e6ab9a02ee6f5"
] | [
"PMCID:PMC9472213"
] | [
"SPAN:6f4d40bf261b9f252002173e"
] | [] | [] | {"qa_id":"QA:aa599e876612d23128bf3e0e","qa_group_id":"QAG:af3e7ef6aec48eae0770a997","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G008","question":"Which exact source passage supports the statement \"The multivariate Cox proportional hazards regression analysis resu... |
QA:ab0cb10d395e2e9fb866dd96 | QAG:fda9753e905fe4e92f867db3 | provenance_qa | exact_evidence_retrieval | provenance_qa | G008 | en | train | Which exact source passage supports the statement "Comparing the efficacy of ICI monotherapy and fruquintinib monotherapy in MSS/pMMR CRC ( 4 , 5 ), the combined therapy improved treatment efficacy; so, we are eagerly awaiting the benefits of fruquintinib coupled with PD-1 inhibitors for more cancer patients"? Return t... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:fc620d5cb8478b8beed44b44","quotes":["Comparing the efficacy of ICI monotherapy and fruquintinib monotherapy in MS... | [
"CLM:fc620d5cb8478b8beed44b44",
"CLM:76b5c39658e904fe9e6f7dd7"
] | [
"PMCID:PMC9472213"
] | [
"SPAN:e0a00bf2b9ea9b661e447b63"
] | [] | [] | {"qa_id":"QA:ab0cb10d395e2e9fb866dd96","qa_group_id":"QAG:fda9753e905fe4e92f867db3","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G008","question":"Which exact source passage supports the statement \"Comparing the efficacy of ICI monotherapy and fruquintinib monothe... |
QA:aca6b82ea6df8d9963078f34 | QAG:840e6b1a46192dbd08576cce | provenance_qa | exact_evidence_retrieval | provenance_qa | G008 | en | train | Which exact source passage supports the statement "Mechanistically, ATG16L1 inhibited type II IFN responses in CRC organoids, and treatment of ATG16L1-deficient cells with a combination of IFNγ and TNF significantly enhanced programmed cell death compared to control CRC organoids"? Return the original wording with pape... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:8498daa1dc0398a703f0e7b1","quotes":["Mechanistically, ATG16L1 suppressed type II IFN responses in CRC organoids, ... | [
"CLM:8498daa1dc0398a703f0e7b1",
"CLM:64822c34f03e6ab9a02ee6f5"
] | [
"PMCID:PMC10517947"
] | [
"SPAN:08c6f32eea3f0982a13e3a0d"
] | [] | [] | {"qa_id":"QA:aca6b82ea6df8d9963078f34","qa_group_id":"QAG:840e6b1a46192dbd08576cce","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G008","question":"Which exact source passage supports the statement \"Mechanistically, ATG16L1 inhibited type II IFN responses in CRC or... |
QA:ad868b71bec5dd4bf9568300 | QAG:f714c75ba46a67c73d6f8f4c | provenance_qa | exact_evidence_retrieval | provenance_qa | G008 | en | train | Which exact source passage supports the statement "While not fully characterized in colorectal cancer, inhibition of TGFβ3 in preclinical models of glioblastoma multiforme was associated with decreased expression of downstream SMAD oncogenes, decreased tumor invasiveness, and dampened TGFβ1/TGFβ2 signaling"? Return the... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:0073c2120ee0a21e8a57f5ce","quotes":["While not fully characterized in colorectal cancer, inhibition of TGFβ3 in p... | [
"CLM:0073c2120ee0a21e8a57f5ce",
"CLM:64822c34f03e6ab9a02ee6f5"
] | [
"PMCID:PMC9648419"
] | [
"SPAN:e6ac2f9c8795770319032ea8"
] | [] | [] | {"qa_id":"QA:ad868b71bec5dd4bf9568300","qa_group_id":"QAG:f714c75ba46a67c73d6f8f4c","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G008","question":"Which exact source passage supports the statement \"While not fully characterized in colorectal cancer, inhibition of ... |
QA:ae02d1f1e2a695377ca6951d | QAG:364f0c3bb5a39d6e3b21fdee | provenance_qa | exact_evidence_retrieval | provenance_qa | G008 | en | train | Which exact source passage supports the statement "This effect was associated with an increased presence of intratumoral NKT cells, B cells, and proinflammatory macrophages and with a reduced percentage of immunosuppressive TAMs. In human CRC tumors, the expression of OLFML3 strongly correlated with markers specific fo... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:24629dc58472ba504c6ac252","quotes":["This effect was associated with an increased presence of intratumoral NKT ce... | [
"CLM:24629dc58472ba504c6ac252",
"CLM:64822c34f03e6ab9a02ee6f5"
] | [
"PMCID:PMC8464773"
] | [
"SPAN:38087b3412f8cc4b518db51f"
] | [] | [] | {"qa_id":"QA:ae02d1f1e2a695377ca6951d","qa_group_id":"QAG:364f0c3bb5a39d6e3b21fdee","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G008","question":"Which exact source passage supports the statement \"This effect was associated with an increased presence of intratumo... |
QA:ae628e5fc33732a755d88936 | QAG:ec2cdcc1cbbbcd4426941849 | provenance_qa | exact_evidence_retrieval | provenance_qa | G008 | en | train | Which exact source passage supports the statement "Altogether, CAF-derived C-6-S promoted M2 polarization and targeting C-6-S with Surfen could subvert the immune-excluded TME in MSS colorectal cancer"? Return the original wording with paper, Claim, and Evidence Span references.
Integrated provenance requirements: ret... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:61387b0c7bf1d1651f77c193","quotes":["Altogether, CAF-derived C-6-S induced M2 polarization and targeting C-6-S wi... | [
"CLM:61387b0c7bf1d1651f77c193",
"CLM:64822c34f03e6ab9a02ee6f5"
] | [
"PMCID:PMC9414301"
] | [
"SPAN:491cb434f4808dde3f98e01c"
] | [] | [] | {"qa_id":"QA:ae628e5fc33732a755d88936","qa_group_id":"QAG:ec2cdcc1cbbbcd4426941849","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G008","question":"Which exact source passage supports the statement \"Altogether, CAF-derived C-6-S promoted M2 polarization and targeti... |
QA:aef6c7c2ee615567a68418f5 | QAG:16af70cdae3d81033f93e7ee | provenance_qa | exact_evidence_retrieval | provenance_qa | G008 | en | train | Which exact source passage supports the statement "26–29 To examine the influence of CCRT on the levels of type I IFN signatures in CRC patients, we first compared 20 CRC patients who received CCRT from the GSE93375 dataset by gene set enrichment analysis (GSEA), and the results indicated that the type I IFN signatures... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:96832e07920d31360b9533fb","quotes":["26–29 To examine the influence of CCRT on the levels of type I IFN signature... | [
"CLM:96832e07920d31360b9533fb",
"CLM:64822c34f03e6ab9a02ee6f5"
] | [
"PMCID:PMC10813565"
] | [
"SPAN:bb72120b098b5ff2ba333191"
] | [] | [] | {"qa_id":"QA:aef6c7c2ee615567a68418f5","qa_group_id":"QAG:16af70cdae3d81033f93e7ee","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G008","question":"Which exact source passage supports the statement \"26–29 To examine the influence of CCRT on the levels of type I IFN... |
QA:afee7e4b8a5aaa698c8cca8a | QAG:dec6a001a41c6f712f6f4e79 | provenance_qa | paper_evidence_availability | provenance_qa | G008 | en | train | Does the current traceable evidence dataset contain a usable Claim and exact source span for paper PMCID:PMC10482431? Explicitly abstain if it does not.
Integrated provenance requirements: report evidence availability or insufficiency without inventing missing full text. Keep each subtask answer separately identifiabl... | {"answer_type":"integrated_provenance","embedded_answer_types":["paper_evidence_availability"],"exact_evidence_retrieval":null,"limited_evidence_retrieval":null,"paper_evidence_availability":{"answer_type":"explicit_evidence_abstention","paper_id":"PMCID:PMC10482431","verdict":"no_released_traceable_claim","reason":"No... | [] | [
"PMCID:PMC10482431"
] | [] | [] | [] | {"qa_id":"QA:afee7e4b8a5aaa698c8cca8a","qa_group_id":"QAG:dec6a001a41c6f712f6f4e79","qa_family":"provenance_qa","subtask_type":"paper_evidence_availability","language":"en","cluster_id":"G008","question":"Does the current traceable evidence dataset contain a usable Claim and exact source span for paper PMCID:PMC1048243... |
QA:b06accb6972c00625711169a | QAG:a6bc4edd636e07ba796ad757 | provenance_qa | exact_evidence_retrieval | provenance_qa | G008 | en | train | Which exact source passage supports the statement "In all MSS-CRC samples, Epigenetic_Mut was increased in the immune subtype (CMS1) and had a strong correlation with immunological features"? Return the original wording with paper, Claim, and Evidence Span references.
Integrated provenance requirements: return the exa... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:68ee47a1c8d40ccbbbff07e9","quotes":["In all MSS-CRC samples, Epigenetic_Mut was elevated in the immune subtype (C... | [
"CLM:68ee47a1c8d40ccbbbff07e9",
"CLM:76b5c39658e904fe9e6f7dd7"
] | [
"PMCID:PMC9720302"
] | [
"SPAN:bf7f8deba2eac63deb8e2d6c"
] | [] | [] | {"qa_id":"QA:b06accb6972c00625711169a","qa_group_id":"QAG:a6bc4edd636e07ba796ad757","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G008","question":"Which exact source passage supports the statement \"In all MSS-CRC samples, Epigenetic_Mut was increased in the immune... |
QA:b33ca1bb18155b2fd8458ca9 | QAG:2f2c52920061b3df64550f9f | provenance_qa | exact_evidence_retrieval | provenance_qa | G008 | en | train | Which exact source passage supports the statement "We found that the risk score was correlated with the infiltration level of CD8 + T cells, activated memory CD4 + T cells, and activated dendritic cells in the TME of MSS-EO-CRC (Fig. 5a )"? Return the original wording with paper, Claim, and Evidence Span references.
I... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:ebcea2e3dd45a18b42a0e98c","quotes":["We found that the risk score was negatively correlated with the infiltration... | [
"CLM:ebcea2e3dd45a18b42a0e98c",
"CLM:64822c34f03e6ab9a02ee6f5"
] | [
"PMCID:PMC10314951"
] | [
"SPAN:5d94e83d1a9690bf6a129f2c"
] | [] | [] | {"qa_id":"QA:b33ca1bb18155b2fd8458ca9","qa_group_id":"QAG:2f2c52920061b3df64550f9f","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G008","question":"Which exact source passage supports the statement \"We found that the risk score was correlated with the infiltration ... |
QA:b4d3c1eb792b8797ea37b9ba | QAG:5ac5b6933d31ab16ad3bf1b5 | provenance_qa | exact_evidence_retrieval | provenance_qa | G008 | en | train | Which exact source passage supports the statement "Although Atg16l1 deletion sensitized to cytotoxicity induced by Type I IFN, TLR3, and TLR4, the cell death triggered by a combination of TNF and IFNγ in Atg16l1 KO CRC organoids was more pronounced compared to other combinations (Supplementary Fig. 10c )"? Return the o... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:150ad85f4c1f7133a3c97c17","quotes":["Although Atg16l1 deletion sensitized CRC organoids to cytotoxicity induced b... | [
"CLM:150ad85f4c1f7133a3c97c17",
"CLM:64822c34f03e6ab9a02ee6f5"
] | [
"PMCID:PMC10517947"
] | [
"SPAN:fafedb95463c3061f9e4086d"
] | [] | [] | {"qa_id":"QA:b4d3c1eb792b8797ea37b9ba","qa_group_id":"QAG:5ac5b6933d31ab16ad3bf1b5","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G008","question":"Which exact source passage supports the statement \"Although Atg16l1 deletion sensitized to cytotoxicity induced by Ty... |
QA:b71422bc52c5e9d6547671ed | QAG:fab250589dfb6917bbfe47ad | provenance_qa | exact_evidence_retrieval | provenance_qa | G008 | en | train | Which exact source passage supports the statement "In contrast to previous reports showing that autophagy inhibition in highly transformed cell lines or primary intestinal epithelial cells sensitized to TNF- or IFNγ-induced cytotoxicity 22 , 46 , IFNγ or TNF alone were unable to induce CRC organoid death in vitro (Fig.... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:8759120492a22b0635b3434b","quotes":["In contrast to previous reports showing that autophagy inhibition in highly ... | [
"CLM:8759120492a22b0635b3434b",
"CLM:64822c34f03e6ab9a02ee6f5"
] | [
"PMCID:PMC10517947"
] | [
"SPAN:7bc755d300deb4aaf987e51e"
] | [] | [] | {"qa_id":"QA:b71422bc52c5e9d6547671ed","qa_group_id":"QAG:fab250589dfb6917bbfe47ad","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G008","question":"Which exact source passage supports the statement \"In contrast to previous reports showing that autophagy inhibition ... |
QA:ba372e3cb13ce25993398033 | QAG:ae3d02dfce00bc83eefa14fb | provenance_qa | exact_evidence_retrieval | provenance_qa | G008 | en | train | Which exact source passage supports the statement "Although high expression of T and B cell signatures predicted improved OS in many cancer types, there was no statistically significant associ- ation observed with CRC"? Return the original wording with paper, Claim, and Evidence Span references.
Integrated provenance ... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:31181f1379c985c122a979f1","quotes":["Although\nhigh expression of T and B cell signatures predicted improved OS\n... | [
"CLM:31181f1379c985c122a979f1",
"CLM:64822c34f03e6ab9a02ee6f5"
] | [
"PMCID:PMC6763253"
] | [
"SPAN:b101d9a1d5a9cda44a009cf6"
] | [] | [] | {"qa_id":"QA:ba372e3cb13ce25993398033","qa_group_id":"QAG:ae3d02dfce00bc83eefa14fb","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G008","question":"Which exact source passage supports the statement \"Although high expression of T and B cell signatures predicted impr... |
QA:badec091cfc6042b9649e683 | QAG:ec1b29f0563a4e6cae21cd8e | provenance_qa | exact_evidence_retrieval | provenance_qa | G008 | en | train | Which exact source passage supports the statement "Combining DNMT inhibitor together with CCRT remarkably increased the therapeutic response to anti-PD-L1 immunotherapy in CRC, especially in MSS-CRC"? Return the original wording with paper, Claim, and Evidence Span references.
Integrated provenance requirements: retur... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:71c873fe5dde30cad48ecf08","quotes":["Combining DNMT inhibitor together with CCRT remarkably enhanced the therapeu... | [
"CLM:71c873fe5dde30cad48ecf08",
"CLM:64822c34f03e6ab9a02ee6f5"
] | [
"PMCID:PMC10813565"
] | [
"SPAN:b58976d6e10e6df790c4c1b9"
] | [] | [] | {"qa_id":"QA:badec091cfc6042b9649e683","qa_group_id":"QAG:ec1b29f0563a4e6cae21cd8e","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G008","question":"Which exact source passage supports the statement \"Combining DNMT inhibitor together with CCRT remarkably increased t... |
QA:bb98faa55ef4aac5c835e019 | QAG:8ba505999851fea307239006 | provenance_qa | exact_evidence_retrieval | provenance_qa | G008 | en | train | Which exact source passage supports the statement "11b ) and caspases were pharmacologically inhibited with z-VAD in Atg16l1 KO CRC organoids"? Return the original wording with paper, Claim, and Evidence Span references.
Integrated provenance requirements: return the exact supporting passage with paper, Claim, and Evi... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:1b507f9c3cea7057be618688","quotes":["To more thoroughly address the contribution of necroptosis and apoptosis to ... | [
"CLM:1b507f9c3cea7057be618688",
"CLM:64822c34f03e6ab9a02ee6f5"
] | [
"PMCID:PMC10517947"
] | [
"SPAN:b8bbb3d6239277b6c768b41a"
] | [] | [] | {"qa_id":"QA:bb98faa55ef4aac5c835e019","qa_group_id":"QAG:8ba505999851fea307239006","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G008","question":"Which exact source passage supports the statement \"11b ) and caspases were pharmacologically inhibited with z-VAD in ... |
QA:bfb77ace1e3bcd10745c259a | QAG:f05874af10c6a4c0092971a2 | provenance_qa | exact_evidence_retrieval | provenance_qa | G008 | en | train | Which exact source passage supports the statement "In this study, we found that PD-L1 promoter methylation was correlated with tumor PD-L1 expression and is an independent biomarker for locally advanced colorectal cancer patients"? Return the original wording with paper, Claim, and Evidence Span references.
Integrated... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:46f8ac2d4c5a43e35a27c14c","quotes":["In this study, we found that PD-L1 promoter methylation is negatively correl... | [
"CLM:46f8ac2d4c5a43e35a27c14c",
"CLM:64822c34f03e6ab9a02ee6f5"
] | [
"PMCID:PMC10813565"
] | [
"SPAN:5a157ea4afa51f29246fb9a4"
] | [] | [] | {"qa_id":"QA:bfb77ace1e3bcd10745c259a","qa_group_id":"QAG:f05874af10c6a4c0092971a2","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G008","question":"Which exact source passage supports the statement \"In this study, we found that PD-L1 promoter methylation was correl... |
QA:c012111ddac5b1db491220e0 | QAG:a7113f166fd9990462082ee8 | provenance_qa | exact_evidence_retrieval | provenance_qa | G008 | en | train | Which exact source passage supports the statement "In addition, MSI-H CRC has more immune cell infiltration [especially tumor-infiltrating lymphocytes (TILs) and type I interferons], which was associated with a better prognosis ( 5 , 9 )"? Return the original wording with paper, Claim, and Evidence Span references.
In... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:4497d72b1ea8a135533f906e","quotes":["In addition, MSI-H CRC has more immune cell infiltration [especially tumor-i... | [
"CLM:4497d72b1ea8a135533f906e"
] | [
"PMCID:PMC7435056"
] | [
"SPAN:13cfda034331ea25adb5953d"
] | [] | [] | {"qa_id":"QA:c012111ddac5b1db491220e0","qa_group_id":"QAG:a7113f166fd9990462082ee8","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G008","question":"Which exact source passage supports the statement \"In addition, MSI-H CRC has more immune cell infiltration [especial... |
QA:c5351c23bbf4342aea77778f | QAG:1bfc396eb1f3a0c76bd60b6e | provenance_qa | paper_evidence_availability | provenance_qa | G008 | en | train | Does the current traceable evidence dataset contain a usable Claim and exact source span for paper PMCID:PMC5214087? Explicitly abstain if it does not.
Integrated provenance requirements: report evidence availability or insufficiency without inventing missing full text. Keep each subtask answer separately identifiable... | {"answer_type":"integrated_provenance","embedded_answer_types":["paper_evidence_availability"],"exact_evidence_retrieval":null,"limited_evidence_retrieval":null,"paper_evidence_availability":{"answer_type":"explicit_evidence_abstention","paper_id":"PMCID:PMC5214087","verdict":"no_released_traceable_claim","reason":"No ... | [] | [
"PMCID:PMC5214087"
] | [] | [] | [] | {"qa_id":"QA:c5351c23bbf4342aea77778f","qa_group_id":"QAG:1bfc396eb1f3a0c76bd60b6e","qa_family":"provenance_qa","subtask_type":"paper_evidence_availability","language":"en","cluster_id":"G008","question":"Does the current traceable evidence dataset contain a usable Claim and exact source span for paper PMCID:PMC5214087... |
QA:c6570f72d461e5d91c785ad5 | QAG:56ef35aa466fb94a7428c14e | provenance_qa | exact_evidence_retrieval | provenance_qa | G008 | en | train | Which exact source passage supports the statement "The Cancer Genome Atlas (TCGA) cohort, GSE39582 cohort, and National Cancer Center (NCC) cohort (24 MSS CRC patients were enrolled in this study between March 2017 and October 2017) were used to validate the clinical features of prognostic signatures"? Return the origi... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:c5f1301c9f8964fbab4a5b17","quotes":["The Cancer Genome Atlas (TCGA) cohort, GSE39582 cohort, and National Cancer ... | [
"CLM:c5f1301c9f8964fbab4a5b17",
"CLM:64822c34f03e6ab9a02ee6f5"
] | [
"PMCID:PMC10129169"
] | [
"SPAN:8ec32d31707cf9ac5a6114ca"
] | [] | [] | {"qa_id":"QA:c6570f72d461e5d91c785ad5","qa_group_id":"QAG:56ef35aa466fb94a7428c14e","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G008","question":"Which exact source passage supports the statement \"The Cancer Genome Atlas (TCGA) cohort, GSE39582 cohort, and Nation... |
QA:c66d7d133511b1c9ee54932c | QAG:1350798e9014a1758bea8c2c | provenance_qa | paper_evidence_availability | provenance_qa | G008 | en | train | Does the current traceable evidence dataset contain a usable Claim and exact source span for paper PMCID:PMC9239344? Explicitly abstain if it does not.
Integrated provenance requirements: report evidence availability or insufficiency without inventing missing full text. Keep each subtask answer separately identifiable... | {"answer_type":"integrated_provenance","embedded_answer_types":["paper_evidence_availability"],"exact_evidence_retrieval":null,"limited_evidence_retrieval":null,"paper_evidence_availability":{"answer_type":"explicit_evidence_abstention","paper_id":"PMCID:PMC9239344","verdict":"no_released_traceable_claim","reason":"No ... | [] | [
"PMCID:PMC9239344"
] | [] | [] | [] | {"qa_id":"QA:c66d7d133511b1c9ee54932c","qa_group_id":"QAG:1350798e9014a1758bea8c2c","qa_family":"provenance_qa","subtask_type":"paper_evidence_availability","language":"en","cluster_id":"G008","question":"Does the current traceable evidence dataset contain a usable Claim and exact source span for paper PMCID:PMC9239344... |
QA:c87d40e49a89634de92ca766 | QAG:d84b20e642ca28265d86c90e | provenance_qa | exact_evidence_retrieval | provenance_qa | G008 | en | train | Which exact source passage supports the statement "Although ICI-based combination therapies have shown certain effectiveness in pMMR/MSS CRC, especially in combination with antiangiogenic agents (Lenvatinib or Regorafenib) that led to an ORR of 20-30% ( 6 , 33 ), most patients still cannot benefit from the combination ... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:e638238421b377ca7c30cbf2","quotes":["Although ICI-based combination therapies have shown certain effectiveness in... | [
"CLM:e638238421b377ca7c30cbf2",
"CLM:76b5c39658e904fe9e6f7dd7"
] | [
"PMCID:PMC9720302"
] | [
"SPAN:e99f8d1515afb4e422a6570b"
] | [] | [] | {"qa_id":"QA:c87d40e49a89634de92ca766","qa_group_id":"QAG:d84b20e642ca28265d86c90e","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G008","question":"Which exact source passage supports the statement \"Although ICI-based combination therapies have shown certain effect... |
QA:ca3467d4f65919fdeab73fae | QAG:a823ee7f02653edf2185861b | provenance_qa | exact_evidence_retrieval | provenance_qa | G008 | en | train | Which exact source passage supports the statement "We hypothesize that the efficacy of immune-checkpoint inhibitors in MSS CRC may be increased by improved priming and T-cell activation of the intratumoral environment through systemic administration of MEK inhibition in combination with an anti PD-L1 antibody for treat... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:dc9b88c65be95df2fa8242e6","quotes":["We hypothesize that the efficacy of immune-checkpoint inhibitors in MSS CRC ... | [
"CLM:dc9b88c65be95df2fa8242e6",
"CLM:64822c34f03e6ab9a02ee6f5"
] | [
"PMCID:PMC9422817"
] | [
"SPAN:94b21760c2bbf6cb4478e4ba"
] | [] | [] | {"qa_id":"QA:ca3467d4f65919fdeab73fae","qa_group_id":"QAG:a823ee7f02653edf2185861b","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G008","question":"Which exact source passage supports the statement \"We hypothesize that the efficacy of immune-checkpoint inhibitors i... |
QA:cc995cb893bebd1875668a4b | QAG:ad9b0ba144d67195dfb4e63a | provenance_qa | exact_evidence_retrieval | provenance_qa | G008 | en | train | Which exact source passage supports the statement "CHFR methylation in CRC cell lines predicted for sensitivity in vitro and in vivo to docetaxel, while MSI-H cell lines were more sensitive to gemcitabine"? Return the original wording with paper, Claim, and Evidence Span references.
Integrated provenance requirements:... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:3027854024085b29c4dbbf4c","quotes":["CHFR methylation in CRC cell lines predicted for sensitivity in vitro and in... | [
"CLM:3027854024085b29c4dbbf4c",
"CLM:64822c34f03e6ab9a02ee6f5"
] | [
"PMCID:PMC3830586"
] | [
"SPAN:2f2f53c4d53903ac4832b8da"
] | [] | [] | {"qa_id":"QA:cc995cb893bebd1875668a4b","qa_group_id":"QAG:ad9b0ba144d67195dfb4e63a","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G008","question":"Which exact source passage supports the statement \"CHFR methylation in CRC cell lines predicted for sensitivity in vi... |
QA:cd9d02245086f6c3cfa0cb18 | QAG:bc865a1def2379a8cb1869eb | provenance_qa | exact_evidence_retrieval | provenance_qa | G008 | en | train | Which exact source passage supports the statement "Mechanistically, ATG16L1 suppressed type II IFN responses in CRC organoids, and treatment of ATG16L1-deficient cells with a combination of IFNγ and TNF increased programmed cell death compared to control CRC organoids"? Return the original wording with paper, Claim, an... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:3295ef576dcc616d2dfc7640","quotes":["Mechanistically, ATG16L1 suppressed type II IFN responses in CRC organoids, ... | [
"CLM:3295ef576dcc616d2dfc7640",
"CLM:64822c34f03e6ab9a02ee6f5"
] | [
"PMCID:PMC10517947"
] | [
"SPAN:08c6f32eea3f0982a13e3a0d"
] | [] | [] | {"qa_id":"QA:cd9d02245086f6c3cfa0cb18","qa_group_id":"QAG:bc865a1def2379a8cb1869eb","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G008","question":"Which exact source passage supports the statement \"Mechanistically, ATG16L1 suppressed type II IFN responses in CRC o... |
QA:cdda19dab193ff4c7b43b59b | QAG:4dbb3ccad9d7e8d0050e16d7 | provenance_qa | exact_evidence_retrieval | provenance_qa | G008 | en | train | Which exact source passage supports the statement "Patients were enrolled in the different studies between 1990 and 2005. Clinicopathological features of our population are in line with other prospective biomarker series (non-clinical trial cohorts), including a relatively elderly population, with stage II representing... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:a873c63cffab88c86b064797","quotes":["Patients were recruited in the different studies between 1990 and 2005. Clin... | [
"CLM:a873c63cffab88c86b064797",
"CLM:64822c34f03e6ab9a02ee6f5"
] | [
"PMCID:PMC6857614"
] | [
"SPAN:17c6fc77a0fed1255781b047",
"SPAN:6372e84fc34a809c838a5a81"
] | [] | [] | {"qa_id":"QA:cdda19dab193ff4c7b43b59b","qa_group_id":"QAG:4dbb3ccad9d7e8d0050e16d7","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G008","question":"Which exact source passage supports the statement \"Patients were enrolled in the different studies between 1990 and 2... |
QA:d0cb19e81d04cb9704a1eb9e | QAG:d2645c489bee0679e57ef82f | provenance_qa | paper_evidence_availability | provenance_qa | G008 | en | train | Does the current traceable evidence dataset contain a usable Claim and exact source span for paper PMCID:PMC10772700? Explicitly abstain if it does not.
Integrated provenance requirements: report evidence availability or insufficiency without inventing missing full text. Keep each subtask answer separately identifiabl... | {"answer_type":"integrated_provenance","embedded_answer_types":["paper_evidence_availability"],"exact_evidence_retrieval":null,"limited_evidence_retrieval":null,"paper_evidence_availability":{"answer_type":"explicit_evidence_abstention","paper_id":"PMCID:PMC10772700","verdict":"no_released_traceable_claim","reason":"No... | [] | [
"PMCID:PMC10772700"
] | [] | [] | [] | {"qa_id":"QA:d0cb19e81d04cb9704a1eb9e","qa_group_id":"QAG:d2645c489bee0679e57ef82f","qa_family":"provenance_qa","subtask_type":"paper_evidence_availability","language":"en","cluster_id":"G008","question":"Does the current traceable evidence dataset contain a usable Claim and exact source span for paper PMCID:PMC1077270... |
QA:d2f61ab7bd2970e25d6f2aea | QAG:a86b465c1460ac334ecb769d | provenance_qa | exact_evidence_retrieval | provenance_qa | G008 | en | train | Which exact source passage locates the statement "Improved survival in metastatic colorectal cancer was associated with adoption of hepatic resection and improved chemotherapy"? If it is only a reference-list entry, explicitly abstain from treating it as sufficient full-text evidence.
Integrated provenance requirement... | {"answer_type":"integrated_provenance","embedded_answer_types":["limited_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":null,"limited_evidence_retrieval":{"answer_type":"limited_evidence_retrieval","claim_id":"CLM:0c6557e4754b7a6d7643fb7a","quotes":["Improved survival in metastatic colore... | [
"CLM:0c6557e4754b7a6d7643fb7a",
"CLM:64822c34f03e6ab9a02ee6f5"
] | [
"PMCID:PMC9648419"
] | [
"SPAN:e137380ac3a6fc1f38a93da9"
] | [] | [] | {"qa_id":"QA:d2f61ab7bd2970e25d6f2aea","qa_group_id":"QAG:a86b465c1460ac334ecb769d","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G008","question":"Which exact source passage locates the statement \"Improved survival in metastatic colorectal cancer was associated wi... |
QA:d45df1761da5afd1e9e3885b | QAG:5a406a58a65903a21cdbbd37 | provenance_qa | exact_evidence_retrieval | provenance_qa | G008 | en | train | Which exact source passage supports the statement "Loss of Atg16l1 increased IFN pathway gene expression in CRC organoids upon IFNγ treatment (Fig. 5a, b )"? Return the original wording with paper, Claim, and Evidence Span references.
Integrated provenance requirements: return the exact supporting passage with paper, ... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:40aafc951a6af1eed8e5716f","quotes":["Loss of Atg16l1 significantly enhanced IFN pathway gene expression in CRC or... | [
"CLM:40aafc951a6af1eed8e5716f",
"CLM:64822c34f03e6ab9a02ee6f5"
] | [
"PMCID:PMC10517947"
] | [
"SPAN:0f0d500c6e8ce6fffa5d8b66"
] | [] | [] | {"qa_id":"QA:d45df1761da5afd1e9e3885b","qa_group_id":"QAG:5a406a58a65903a21cdbbd37","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G008","question":"Which exact source passage supports the statement \"Loss of Atg16l1 increased IFN pathway gene expression in CRC organ... |
QA:d4a5f7b996fde1574817566e | QAG:5b312589c05371e395cb938f | provenance_qa | exact_evidence_retrieval | provenance_qa | G008 | en | train | Which exact source passage supports the statement "The results showed that both MSI-H CRC and COAD had an inflammatory TME, as indicated by increased numbers of plasma cells, CD8 + T cells, activated memory CD4 + T cells, follicular T helper cells, NK cells, M1 macrophages and neutrophils and significantly decreased nu... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:2141cf84a85a2517d73f7be5","quotes":["The results showed that both MSI-H CRC and COAD had an inflammatory TME, as ... | [
"CLM:2141cf84a85a2517d73f7be5",
"CLM:64822c34f03e6ab9a02ee6f5"
] | [
"PMCID:PMC7435056"
] | [
"SPAN:5abf6e7e7f2dc6a71b96e6d2"
] | [] | [] | {"qa_id":"QA:d4a5f7b996fde1574817566e","qa_group_id":"QAG:5b312589c05371e395cb938f","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G008","question":"Which exact source passage supports the statement \"The results showed that both MSI-H CRC and COAD had an inflammator... |
QA:d4d9ca1ffb8d55a0ab881bd1 | QAG:799bda27ff651a1f4b8bd542 | provenance_qa | exact_evidence_retrieval | provenance_qa | G008 | en | train | Which exact source passage supports the statement "Studies have shown that immune CPI monotherapy, including PD-1 blockade or anti-CTLA-4 therapy was associated with virtually no activity in patients with pMMR/non-MSI-H metastatic CRC ( Asaoka et al., 2015 ; Le et al., 2017 ), while approximately 10–15% of CRC tumors a... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:8abfecb6892306926002be2d","quotes":["Studies have shown that immune CPI monotherapy, including PD-1 blockade or a... | [
"CLM:8abfecb6892306926002be2d",
"CLM:76b5c39658e904fe9e6f7dd7"
] | [
"PMCID:PMC7212380"
] | [
"SPAN:6dc39dfa43d2ca1c1df4235b"
] | [] | [] | {"qa_id":"QA:d4d9ca1ffb8d55a0ab881bd1","qa_group_id":"QAG:799bda27ff651a1f4b8bd542","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G008","question":"Which exact source passage supports the statement \"Studies have shown that immune CPI monotherapy, including PD-1 blo... |
QA:d7639646d2109ead2416d485 | QAG:db9cd09e113520187482d0cc | provenance_qa | exact_evidence_retrieval | provenance_qa | G008 | en | train | Which exact source passage supports the statement "To identify the potential drugs having different sensitivity in subgroup patients, we predicted that MSS-LO-CRC patients were more sensitive to OSI.906, while MSS-EO-CRC ones were more sensitive to PF.4708671 and Salubrinal (Fig. 2f–h )"? Return the original wording wi... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:9f5a3614b420e119f05baea5","quotes":["To identify the potential drugs having different sensitivity in subgroup pat... | [
"CLM:9f5a3614b420e119f05baea5",
"CLM:64822c34f03e6ab9a02ee6f5"
] | [
"PMCID:PMC10314951"
] | [
"SPAN:722aa2cade476e771ee12be0"
] | [] | [] | {"qa_id":"QA:d7639646d2109ead2416d485","qa_group_id":"QAG:db9cd09e113520187482d0cc","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G008","question":"Which exact source passage supports the statement \"To identify the potential drugs having different sensitivity in su... |
QA:d9396e71197475b20e740200 | QAG:50e4c7a93a661583c50cc51a | provenance_qa | exact_evidence_retrieval | provenance_qa | G008 | en | train | Which exact source passage supports the statement "b Differential expression of representative IFNγ promoted genes between Atg16l1 KO ( n = 2) and WT ( n = 2) CRC organoids in either untreated or IFNγ-treated conditions. c WT or Atg16l1 KO CRC organoids treated as indicated and stained with propidium iodide (PI)"? Retu... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:3c04c2887e528f45ee8d71e1","quotes":["Fig. 5 Atg16l1 loss sensitizes CRC organoids to TNF + IFNγ-induced cell deat... | [
"CLM:3c04c2887e528f45ee8d71e1",
"CLM:64822c34f03e6ab9a02ee6f5"
] | [
"PMCID:PMC10517947"
] | [
"SPAN:730dfccea9717bc572afb42d"
] | [] | [] | {"qa_id":"QA:d9396e71197475b20e740200","qa_group_id":"QAG:50e4c7a93a661583c50cc51a","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G008","question":"Which exact source passage supports the statement \"b Differential expression of representative IFNγ promoted genes be... |
QA:da16c2e45958dd86d02a29bb | QAG:4436fcf126051661a2ffcdcd | provenance_qa | exact_evidence_retrieval | provenance_qa | G008 | en | train | Which exact source passage supports the statement "Deletion of Ripk3 partially rescued TNF + IFNγ promoted death in Atg16l1 KO CRC organoids, and cell death was completely blocked by addition of z-VAD to cells doubly deficient in ATG16L1 and RIPK3 (Fig. 5f )"? Return the original wording with paper, Claim, and Evidence... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:8cb92836a1e0a49f87340632","quotes":["Deletion of Ripk3 partially rescued TNF + IFNγ-induced death in Atg16l1 KO C... | [
"CLM:8cb92836a1e0a49f87340632",
"CLM:64822c34f03e6ab9a02ee6f5"
] | [
"PMCID:PMC10517947"
] | [
"SPAN:0078b69ff4642c5f5acef659"
] | [] | [] | {"qa_id":"QA:da16c2e45958dd86d02a29bb","qa_group_id":"QAG:4436fcf126051661a2ffcdcd","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G008","question":"Which exact source passage supports the statement \"Deletion of Ripk3 partially rescued TNF + IFNγ promoted death in A... |
QA:dafe8a0b2442ba39910469c9 | QAG:610c54250ca59ad64a82acad | provenance_qa | exact_evidence_retrieval | provenance_qa | G008 | en | train | Which exact source passage supports the statement "This study aims to evaluate intra-tumor heterogeneity in MSS CRC by their SCNA characteristics"? Return the original wording with paper, Claim, and Evidence Span references.
Integrated provenance requirements: return the exact supporting passage with paper, Claim, and... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:7df8bee92287278acb9ec213","quotes":["This study aimed to investigate intra-tumor heterogeneity in MSS CRC by thei... | [
"CLM:7df8bee92287278acb9ec213",
"CLM:64822c34f03e6ab9a02ee6f5"
] | [
"PMCID:PMC10129169"
] | [
"SPAN:05ace1dd914ceaccedab2333"
] | [] | [] | {"qa_id":"QA:dafe8a0b2442ba39910469c9","qa_group_id":"QAG:610c54250ca59ad64a82acad","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G008","question":"Which exact source passage supports the statement \"This study aims to evaluate intra-tumor heterogeneity in MSS CRC b... |
QA:dd396ded838fd6c490973243 | QAG:bed1d4484f0a4952108b432c | provenance_qa | exact_evidence_retrieval | provenance_qa | G008 | en | train | Which exact source passage supports the statement "FIGURE 3 MSI-H CRC was associated with activated antitumor immunity"? Return the original wording with paper, Claim, and Evidence Span references.
Integrated provenance requirements: return the exact supporting passage with paper, Claim, and Evidence Span references; ... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:2a42e576bae9de92ea340099","quotes":["FIGURE 3 MSI-H CRC was associated with activated antitumor immunity."],"cita... | [
"CLM:2a42e576bae9de92ea340099",
"CLM:64822c34f03e6ab9a02ee6f5"
] | [
"PMCID:PMC7435056"
] | [
"SPAN:1a4a59be94a0896d3e697828"
] | [] | [] | {"qa_id":"QA:dd396ded838fd6c490973243","qa_group_id":"QAG:bed1d4484f0a4952108b432c","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G008","question":"Which exact source passage supports the statement \"FIGURE 3 MSI-H CRC was associated with activated antitumor immunit... |
QA:dedf4cc676386ae93f37f5d0 | QAG:f98b97fddc24af7363dbdadb | provenance_qa | exact_evidence_retrieval | provenance_qa | G008 | en | train | Which exact source passage supports the statement "Indeed, in patients with colorectal cancer who undergo complete surgical resection, the detection of ctDNA was associated with inevitable disease recurrence and therefore serves as a surrogate for the existence of persistent minimal residual (micrometastatic) disease"?... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:d5caa751dcf56ae329f433f5","quotes":["Indeed, in patients with colorectal cancer who undergo complete surgical res... | [
"CLM:d5caa751dcf56ae329f433f5",
"CLM:64822c34f03e6ab9a02ee6f5"
] | [
"PMCID:PMC9648419"
] | [
"SPAN:60dc1441410d527081b84ca5"
] | [] | [] | {"qa_id":"QA:dedf4cc676386ae93f37f5d0","qa_group_id":"QAG:f98b97fddc24af7363dbdadb","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G008","question":"Which exact source passage supports the statement \"Indeed, in patients with colorectal cancer who undergo complete su... |
QA:e03322a243ecd86951f7ad9b | QAG:013adef1f7ad8ab2a09ff184 | provenance_qa | exact_evidence_retrieval | provenance_qa | G008 | en | train | Which exact source passage supports the statement "ICIs combined with VEGFR2 blockade has shown increased efficacy in MSS colorectal cancer preclinical models ( 4 )"? Return the original wording with paper, Claim, and Evidence Span references.
Integrated provenance requirements: return the exact supporting passage wit... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:320e44cec9e609b46e320e7c","quotes":["ICIs combined with VEGFR2 blockade has shown enhanced efficacy in MSS colore... | [
"CLM:320e44cec9e609b46e320e7c",
"CLM:64822c34f03e6ab9a02ee6f5"
] | [
"PMCID:PMC9414301"
] | [
"SPAN:1c0c10d7477b3564b45d15f4"
] | [] | [] | {"qa_id":"QA:e03322a243ecd86951f7ad9b","qa_group_id":"QAG:013adef1f7ad8ab2a09ff184","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G008","question":"Which exact source passage supports the statement \"ICIs combined with VEGFR2 blockade has shown increased efficacy in... |
QA:e0abd48a5e4124481a2684f5 | QAG:f8fe54d0b342fdaa1ba8da42 | provenance_qa | exact_evidence_retrieval | provenance_qa | G008 | en | train | Which exact source passage supports the statement "Mouse PMs (C) and human colorectal cancer TAMs (D) received various concentrations of C-6-S. Flow cytometry detected the CD11c−CD206+ or CD86−CD163+ M2 macrophages"? Return the original wording with paper, Claim, and Evidence Span references.
Integrated provenance req... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:5e9f309e4efb7f6b38702222","quotes":["Mouse PMs (C) and human colorectal cancer TAMs (D) were treated with various... | [
"CLM:5e9f309e4efb7f6b38702222",
"CLM:64822c34f03e6ab9a02ee6f5"
] | [
"PMCID:PMC9414301"
] | [
"SPAN:ad95e7e2f7214a9e1a2e2cb4"
] | [] | [] | {"qa_id":"QA:e0abd48a5e4124481a2684f5","qa_group_id":"QAG:f8fe54d0b342fdaa1ba8da42","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G008","question":"Which exact source passage supports the statement \"Mouse PMs (C) and human colorectal cancer TAMs (D) received variou... |
QA:e1596ab260a06f11728b89f4 | QAG:78f2978c8b8b8ff8acd2a648 | provenance_qa | exact_evidence_retrieval | provenance_qa | G008 | en | train | Which exact source passage supports the statement "Based on carefully collected and curated genomic and clinical data and immune-related algorithms, we determined that MSI-H CRC was associated with enhanced tumor immunogenicity (including NAL, TMB, and DDR mutations) and an inflamed TME (including high expression level... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:7c490a6b1190b25486e6a054","quotes":["Based on carefully collected and curated genomic and clinical data and immun... | [
"CLM:7c490a6b1190b25486e6a054",
"CLM:64822c34f03e6ab9a02ee6f5"
] | [
"PMCID:PMC7435056"
] | [
"SPAN:a1a08a634855e47d6cb44fef"
] | [] | [] | {"qa_id":"QA:e1596ab260a06f11728b89f4","qa_group_id":"QAG:78f2978c8b8b8ff8acd2a648","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G008","question":"Which exact source passage supports the statement \"Based on carefully collected and curated genomic and clinical data... |
QA:e17a34b798ac8f40080b367e | QAG:1925fc2a7fd782ad20351a69 | provenance_qa | exact_evidence_retrieval | provenance_qa | G008 | en | train | Which exact source passage supports the statement "Patients were diagnosed with colorectal cancer and received surgery in 2014–2018. Signed informed consents were obtained from all the patients for the use of clinical information and tissue samples"? Return the original wording with paper, Claim, and Evidence Span refe... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:2be1cc5f7d9f109bca8841d7","quotes":["Patients were diagnosed with colorectal cancer and received surgery in 2014–... | [
"CLM:2be1cc5f7d9f109bca8841d7",
"CLM:64822c34f03e6ab9a02ee6f5"
] | [
"PMCID:PMC9414301"
] | [
"SPAN:d83fec774654f3daafa84837"
] | [] | [] | {"qa_id":"QA:e17a34b798ac8f40080b367e","qa_group_id":"QAG:1925fc2a7fd782ad20351a69","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G008","question":"Which exact source passage supports the statement \"Patients were diagnosed with colorectal cancer and received surger... |
QA:e726c8032192707562279c9b | QAG:508fd48720632adc774aace7 | provenance_qa | exact_evidence_retrieval | provenance_qa | G008 | en | train | Which exact source passage supports the statement "Although tumor burden in the Atg16l1 KO group remained decreased compared to the WT group (approximately a 2-fold difference in BLI signal after 4 weeks), all NSG mice administered with Atg16l1 KO CRC organoids presented with large tumor nodules (Fig. 2j )"? Return the... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:e75a4fa48a7bfcd3d91a85fc","quotes":["Although tumor burden in the Atg16l1 KO group remained significantly decreas... | [
"CLM:e75a4fa48a7bfcd3d91a85fc",
"CLM:64822c34f03e6ab9a02ee6f5"
] | [
"PMCID:PMC10517947"
] | [
"SPAN:02578620c630ba3c7e071251"
] | [] | [] | {"qa_id":"QA:e726c8032192707562279c9b","qa_group_id":"QAG:508fd48720632adc774aace7","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G008","question":"Which exact source passage supports the statement \"Although tumor burden in the Atg16l1 KO group remained decreased c... |
QA:e835fa0c66f8e3369d079e83 | QAG:83cd659a81c11cc4c0708909 | provenance_qa | exact_evidence_retrieval | provenance_qa | G008 | en | train | Which exact source passage supports the statement "Furthermore, an AOM/DSS promoted colorectal cancer mouse model ( 37 ), which could reflect the pathologic process of colorectal cancer, was utilized to validate treatment efficacy"? Return the original wording with paper, Claim, and Evidence Span references.
Integrate... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:0f52728008478d10e1369419","quotes":["Furthermore, an AOM/DSS-induced colorectal cancer mouse model ( 37 ), which ... | [
"CLM:0f52728008478d10e1369419",
"CLM:64822c34f03e6ab9a02ee6f5"
] | [
"PMCID:PMC9414301"
] | [
"SPAN:1445f770627c522634030860"
] | [] | [] | {"qa_id":"QA:e835fa0c66f8e3369d079e83","qa_group_id":"QAG:83cd659a81c11cc4c0708909","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G008","question":"Which exact source passage supports the statement \"Furthermore, an AOM/DSS promoted colorectal cancer mouse model ( 3... |
QA:ea6a1ee07e62d683aa081b77 | QAG:6f48432a2cce287fed0069b9 | provenance_qa | exact_evidence_retrieval | provenance_qa | G008 | en | train | Which exact source passage supports the statement "In addition, in the TCGA-CRC cohort, the NAL in the MSI-H CRC group was higher than that in the MSS/MSI-L group ( P < 0.05; Figure 2D )"? Return the original wording with paper, Claim, and Evidence Span references.
Integrated provenance requirements: return the exact ... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:c6aeb0834dc33bf02aa4b0ba","quotes":["In addition, in the TCGA-CRC cohort, the NAL in the MSI-H CRC group was sign... | [
"CLM:c6aeb0834dc33bf02aa4b0ba",
"CLM:64822c34f03e6ab9a02ee6f5"
] | [
"PMCID:PMC7435056"
] | [
"SPAN:ddef40167acddb03635e1e77"
] | [] | [] | {"qa_id":"QA:ea6a1ee07e62d683aa081b77","qa_group_id":"QAG:6f48432a2cce287fed0069b9","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G008","question":"Which exact source passage supports the statement \"In addition, in the TCGA-CRC cohort, the NAL in the MSI-H CRC grou... |
QA:ec3e2d03816823b1d66e0494 | QAG:85c77dccdd9d28931bf08ce2 | provenance_qa | exact_evidence_retrieval | provenance_qa | G008 | en | train | Which exact source passage supports the statement "On the other hand, the expression levels of immune checkpoints annuls the prognostic relevance of CytoLym in highly immunogenic colon tumors and predicted a poor outcome in MSI CRC patients"? Return the original wording with paper, Claim, and Evidence Span references.
... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:b5e421e84f0f5ba1196796fa","quotes":["On the other hand, the expression levels of immune checkpoints annuls the pr... | [
"CLM:b5e421e84f0f5ba1196796fa",
"CLM:64822c34f03e6ab9a02ee6f5"
] | [
"PMCID:PMC6857614"
] | [
"SPAN:b19249d3302cec0a09441a62"
] | [] | [] | {"qa_id":"QA:ec3e2d03816823b1d66e0494","qa_group_id":"QAG:85c77dccdd9d28931bf08ce2","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G008","question":"Which exact source passage supports the statement \"On the other hand, the expression levels of immune checkpoints ann... |
QA:ed621f8e486a5a57d1e67bcc | QAG:824846423263fc6e4bfdb608 | provenance_qa | exact_evidence_retrieval | provenance_qa | G008 | en | train | Which exact source passage supports the statement "ARID1A, an AT-rich interactive domain-containing protein 1A, is a component of the switching defective/sucrose non-fermenting (SWI/SNF) complex that plays a role in chromatin remodeling ( 19 ), and increasing evidence suggests that ARID1A alterations was correlated wit... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:64822c34f03e6ab9a02ee6f5","quotes":["ARID1A, an AT-rich interactive domain-containing protein 1A, is a component ... | [
"CLM:64822c34f03e6ab9a02ee6f5",
"CLM:0073c2120ee0a21e8a57f5ce"
] | [
"PMCID:PMC9720302"
] | [
"SPAN:601775bf3cf031287ad80a55"
] | [] | [] | {"qa_id":"QA:ed621f8e486a5a57d1e67bcc","qa_group_id":"QAG:824846423263fc6e4bfdb608","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G008","question":"Which exact source passage supports the statement \"ARID1A, an AT-rich interactive domain-containing protein 1A, is a ... |
QA:ee67cdf76ad31bbf6c6817bb | QAG:222e834484bded3cb237d6dd | provenance_qa | exact_evidence_retrieval | provenance_qa | G008 | en | train | Which exact source passage supports the statement "Our study included 110 MSS/pMMR CRC patients who received the combination regimen of fruquintinib and PD-1 inhibitors"? Return the original wording with paper, Claim, and Evidence Span references.
Integrated provenance requirements: return the exact supporting passage... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification","cross_paper_provenance"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:187792abec08d7cee4862b6a","quotes":["Our study included 110 MSS/pMMR CRC patients who re... | [
"CLM:187792abec08d7cee4862b6a",
"CLM:64822c34f03e6ab9a02ee6f5",
"CLM:ae130298a1757b7ee402997a"
] | [
"PMCID:PMC9472213",
"PMCID:PMC7212380"
] | [
"SPAN:c469af1f48069fbc99c3bd50",
"SPAN:13cf1ac66618d7b7cb327650"
] | [
"ASC2:2d400c71b0e1fb12392e554d"
] | [
"HYP:DCH:0e0882bbf594b03acc5b24c8"
] | {"qa_id":"QA:ee67cdf76ad31bbf6c6817bb","qa_group_id":"QAG:222e834484bded3cb237d6dd","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G008","question":"Which exact source passage supports the statement \"Our study included 110 MSS/pMMR CRC patients who received the comb... |
QA:ee839369229e6077dba89c53 | QAG:0165d5980200515cb025bb1e | provenance_qa | exact_evidence_retrieval | provenance_qa | G008 | en | train | Which exact source passage supports the statement "Moreover, KRAS mutation promotes an immune-suppressive profile in CRC and led to anti-PD1 immune therapy resistance by promoting myeloid-derived suppressor cell (MDSC) migration into the tumor microenvironment. Taken together, we speculated that there was a suppressive... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:60b856d734684298997e2223","quotes":["Another study has also reported this aberrant phenomenon that SCNA levels po... | [
"CLM:60b856d734684298997e2223",
"CLM:76b5c39658e904fe9e6f7dd7"
] | [
"PMCID:PMC10129169"
] | [
"SPAN:f77f9889f95b87ee154e5487"
] | [] | [] | {"qa_id":"QA:ee839369229e6077dba89c53","qa_group_id":"QAG:0165d5980200515cb025bb1e","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G008","question":"Which exact source passage supports the statement \"Moreover, KRAS mutation promotes an immune-suppressive profile in ... |
QA:f1ef08016c93081296d23916 | QAG:729874d944d30c377380d1ba | provenance_qa | exact_evidence_retrieval | provenance_qa | G008 | en | train | Which exact source passage supports the statement "We hypothesize that the efficacy of immune-checkpoint inhibitors in MSS CRC may be enhanced by improved priming and T-cell activation of the intratumoral environment through systemic administration of MEK inhibition in combination with an anti PD-L1 antibody for treatm... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:6b941dc0e10ae8a3c94344d2","quotes":["We hypothesize that the efficacy of immune-checkpoint inhibitors in MSS CRC ... | [
"CLM:6b941dc0e10ae8a3c94344d2",
"CLM:64822c34f03e6ab9a02ee6f5"
] | [
"PMCID:PMC9422817"
] | [
"SPAN:94b21760c2bbf6cb4478e4ba"
] | [] | [] | {"qa_id":"QA:f1ef08016c93081296d23916","qa_group_id":"QAG:729874d944d30c377380d1ba","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G008","question":"Which exact source passage supports the statement \"We hypothesize that the efficacy of immune-checkpoint inhibitors i... |
QA:f2077054dbadea2f9e66bff4 | QAG:27176c38534691e037d2e2ef | provenance_qa | exact_evidence_retrieval | provenance_qa | G008 | en | train | Which exact source passage supports the statement "Deletion of Ripk3 partially rescued TNF + IFNγ-induced death in Atg16l1 KO CRC organoids, and cell death was completely inhibited by addition of z-VAD to cells doubly deficient in ATG16L1 and RIPK3 (Fig. 5f )"? Return the original wording with paper, Claim, and Evidenc... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:70c860d2a4233b2d0b161ab5","quotes":["Deletion of Ripk3 partially rescued TNF + IFNγ-induced death in Atg16l1 KO C... | [
"CLM:70c860d2a4233b2d0b161ab5",
"CLM:64822c34f03e6ab9a02ee6f5"
] | [
"PMCID:PMC10517947"
] | [
"SPAN:0078b69ff4642c5f5acef659"
] | [] | [] | {"qa_id":"QA:f2077054dbadea2f9e66bff4","qa_group_id":"QAG:27176c38534691e037d2e2ef","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G008","question":"Which exact source passage supports the statement \"Deletion of Ripk3 partially rescued TNF + IFNγ-induced death in At... |
QA:f3f6027c8cbd889c18c0663e | QAG:5322993068fcb3955f5f4586 | provenance_qa | exact_evidence_retrieval | provenance_qa | G008 | en | train | Which exact source passage supports the statement "e Immunoblot analysis of the indicated phosphorylated and total proteins in WT or Atg16l1 KO CRC organoids promoted with combinations of TNF + IFNγ for 4 or 18 h. * indicates non-specific bands"? Return the original wording with paper, Claim, and Evidence Span referenc... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:baa1a5a65a2e412f5b6f0fca","quotes":["Groups compared using two-way ANOVA. e Immunoblot analysis of the indicated ... | [
"CLM:baa1a5a65a2e412f5b6f0fca",
"CLM:64822c34f03e6ab9a02ee6f5"
] | [
"PMCID:PMC10517947"
] | [
"SPAN:34029ad18a124e850fefa97b"
] | [] | [] | {"qa_id":"QA:f3f6027c8cbd889c18c0663e","qa_group_id":"QAG:5322993068fcb3955f5f4586","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G008","question":"Which exact source passage supports the statement \"e Immunoblot analysis of the indicated phosphorylated and total pr... |
QA:f4caadb19f43aa26939638d9 | QAG:8b1fe2db60402688ec032f05 | provenance_qa | exact_evidence_retrieval | provenance_qa | G008 | en | train | Which exact source passage supports the statement "From August 2019 to November 2021, patients with MSS/pMMR advanced CRC receiving fruquintinib plus PD-1 inhibitors at the First Affiliated Hospital of Zhengzhou University were included in this single-center retrospective study"? Return the original wording with paper,... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:d0caf3bc281ac6f25622cc75","quotes":["From August 2019 to November 2021, patients with MSS/pMMR advanced CRC recei... | [
"CLM:d0caf3bc281ac6f25622cc75",
"CLM:64822c34f03e6ab9a02ee6f5"
] | [
"PMCID:PMC9472213"
] | [
"SPAN:b12e7670a1d3ff8810511a02"
] | [] | [] | {"qa_id":"QA:f4caadb19f43aa26939638d9","qa_group_id":"QAG:8b1fe2db60402688ec032f05","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G008","question":"Which exact source passage supports the statement \"From August 2019 to November 2021, patients with MSS/pMMR advanced... |
QA:f514171e807c9728fcf24e52 | QAG:644e3e04283029d5923d46f7 | provenance_qa | exact_evidence_retrieval | provenance_qa | G008 | en | train | Which exact source passage supports the statement "Then, we explored the effects of GQD and anti-mouse PD-1 combination therapy on xenograft tumours in mice promoted using the mouse colorectal carcinoma cell line colorectal 26 (CT26), which is known to be MSS"? Return the original wording with paper, Claim, and Evidenc... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification","cross_paper_provenance"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:fb6a0c9817f49af49dcab0f4","quotes":["Then, we explored the effects of GQD and anti-mouse... | [
"CLM:fb6a0c9817f49af49dcab0f4",
"CLM:76b5c39658e904fe9e6f7dd7",
"CLM:ae130298a1757b7ee402997a",
"CLM:187792abec08d7cee4862b6a",
"CLM:22c7b7919832fb99c8ebd90c"
] | [
"PMCID:PMC6538740",
"PMCID:PMC7212380",
"PMCID:PMC9472213"
] | [
"SPAN:61b095271cf01ea457cdfcab",
"SPAN:13cf1ac66618d7b7cb327650",
"SPAN:c469af1f48069fbc99c3bd50",
"SPAN:5a1e753cf8e56545027355e2"
] | [
"ASC2:2d400c71b0e1fb12392e554d",
"ASC2:3587d1e0ae09244af1b2c624"
] | [
"HYP:DCH:724b8679e63c81c663504608"
] | {"qa_id":"QA:f514171e807c9728fcf24e52","qa_group_id":"QAG:644e3e04283029d5923d46f7","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G008","question":"Which exact source passage supports the statement \"Then, we explored the effects of GQD and anti-mouse PD-1 combinati... |
QA:f5df50758817be3a86c2beb4 | QAG:30771ba3cf021d2115a947df | provenance_qa | exact_evidence_retrieval | provenance_qa | G008 | en | train | Which exact source passage supports the statement "Although the incidence of late-onset CRC (LO-CRC) diagnosed in patients 50 years or older has steadily declined over the last two decades in most Western countries 2 , the cases of early-onset CRC (EO-CRC) diagnosed in those younger than 50 years have increased alarmin... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:f8aaecc8214a85875699ec74","quotes":["Although the incidence of late-onset CRC (LO-CRC) diagnosed in patients 50 y... | [
"CLM:f8aaecc8214a85875699ec74",
"CLM:64822c34f03e6ab9a02ee6f5"
] | [
"PMCID:PMC10314951"
] | [
"SPAN:b3d2bdbbe87cf1b978292a79"
] | [] | [] | {"qa_id":"QA:f5df50758817be3a86c2beb4","qa_group_id":"QAG:30771ba3cf021d2115a947df","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G008","question":"Which exact source passage supports the statement \"Although the incidence of late-onset CRC (LO-CRC) diagnosed in pat... |
QA:f7aa841aeaab7cce3f3e8a68 | QAG:6e6e1cc7094507cb0aba9a82 | provenance_qa | exact_evidence_retrieval | provenance_qa | G008 | en | train | Which exact source passage supports the statement "Using “ctDNA-positive” status as a surrogate for remnant micrometastatic colorectal cancer, we conducted a pilot study in patients with liver-limited mCRC who had no clinically evident disease following resection and completion of all standard-of-care therapy, to deter... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:cdb0ec64c15f4a0a6bdc8ac2","quotes":["Using “ctDNA-positive” status as a surrogate for remnant micrometastatic col... | [
"CLM:cdb0ec64c15f4a0a6bdc8ac2"
] | [
"PMCID:PMC9648419"
] | [
"SPAN:a6ffae8657fdc0f6a49ebf4d"
] | [] | [] | {"qa_id":"QA:f7aa841aeaab7cce3f3e8a68","qa_group_id":"QAG:6e6e1cc7094507cb0aba9a82","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G008","question":"Which exact source passage supports the statement \"Using “ctDNA-positive” status as a surrogate for remnant micrometa... |
QA:fa4fbf5e9d2dc8bf9ce6cae0 | QAG:07e8fd78e9a167033cec7cd5 | provenance_qa | exact_evidence_retrieval | provenance_qa | G008 | en | train | Which exact source passage supports the statement "We found that type I IFN signatures such as CXCL9, CXCL10, IFI27, IFI44, ISG15 and ISG20 was correlated with PD-L1 mRNA in CRC patients of TCGA database ( Figure 1(b ))"? Return the original wording with paper, Claim, and Evidence Span references.
Integrated provenanc... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:dcae02d045c61ddf80a13a4f","quotes":["We found that type I IFN signatures such as CXCL9, CXCL10, IFI27, IFI44, ISG... | [
"CLM:dcae02d045c61ddf80a13a4f",
"CLM:64822c34f03e6ab9a02ee6f5"
] | [
"PMCID:PMC10813565"
] | [
"SPAN:26d0b2e86cf4b7ccd33abe59"
] | [] | [] | {"qa_id":"QA:fa4fbf5e9d2dc8bf9ce6cae0","qa_group_id":"QAG:07e8fd78e9a167033cec7cd5","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G008","question":"Which exact source passage supports the statement \"We found that type I IFN signatures such as CXCL9, CXCL10, IFI27, ... |
QA:fabfe997e46f656e76bf9b47 | QAG:8a911338558d0f8c6b567b0d | provenance_qa | exact_evidence_retrieval | provenance_qa | G008 | en | train | Which exact source passage supports the statement "Immunohistochemical test for MLH1 and MSH2 expression predicted clinical outcome in stage II and III colorectal cancer patients"? Return the original wording with paper, Claim, and Evidence Span references.
Integrated provenance requirements: return the exact supporti... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:7c021c46e9f058c2723a5774","quotes":["24. Lanza G, Gafà R, Santini A, Maestri I, Guerzoni\nL, Cavazzini L. Immunoh... | [
"CLM:7c021c46e9f058c2723a5774",
"CLM:64822c34f03e6ab9a02ee6f5"
] | [
"PMCID:PMC6763253"
] | [
"SPAN:b265d0c2826336631d628fd9"
] | [] | [] | {"qa_id":"QA:fabfe997e46f656e76bf9b47","qa_group_id":"QAG:8a911338558d0f8c6b567b0d","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G008","question":"Which exact source passage supports the statement \"Immunohistochemical test for MLH1 and MSH2 expression predicted cl... |
QA:fcb3099eeb180c60baa4ffee | QAG:5f3c6450f0dac70e95512876 | provenance_qa | exact_evidence_retrieval | provenance_qa | G008 | en | train | Which exact source passage supports the statement "Using “ctDNA-positive” status as a surrogate for remnant micrometastatic colorectal cancer, we conducted a pilot study in patients with liver-limited mCRC who had no clinically evident disease following resection and completion of all standard-of-care therapy, to deter... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:0314bf7f076fe215ec310556","quotes":["Using “ctDNA-positive” status as a surrogate for remnant micrometastatic col... | [
"CLM:0314bf7f076fe215ec310556"
] | [
"PMCID:PMC9648419"
] | [
"SPAN:3b4163a91ab2cd42c54d2b2e"
] | [] | [] | {"qa_id":"QA:fcb3099eeb180c60baa4ffee","qa_group_id":"QAG:5f3c6450f0dac70e95512876","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G008","question":"Which exact source passage supports the statement \"Using “ctDNA-positive” status as a surrogate for remnant micrometa... |
QA:fcb967057a52e4402365ca22 | QAG:c5d98104e6591bb7d14a5d1b | provenance_qa | exact_evidence_retrieval | provenance_qa | G008 | en | train | Which exact source passage supports the statement "But autonomous release of IFNβ from irradiated colorectal cancer cells mainly promoted tumor PD-L1 expression ( Figure 1(e ))"? Return the original wording with paper, Claim, and Evidence Span references.
Integrated provenance requirements: return the exact supporting... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:97df1b121ef76a455da4a633","quotes":["But autonomous release of IFNβ from irradiated colorectal cancer cells mainl... | [
"CLM:97df1b121ef76a455da4a633",
"CLM:64822c34f03e6ab9a02ee6f5"
] | [
"PMCID:PMC10813565"
] | [
"SPAN:95eac2f3be67993b27f4587c"
] | [] | [] | {"qa_id":"QA:fcb967057a52e4402365ca22","qa_group_id":"QAG:c5d98104e6591bb7d14a5d1b","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G008","question":"Which exact source passage supports the statement \"But autonomous release of IFNβ from irradiated colorectal cancer c... |
QA:fd63df9d0fb2d6ddd45f7fe7 | QAG:cf50adaceb8a5235fabbec66 | provenance_qa | exact_evidence_retrieval | provenance_qa | G008 | en | train | Which exact source passage supports the statement "Patients who had received prior PD-1 or PD-L1 therapy were eligible for inclusion in cohort 7A if it was their most recent/current line of therapy and treatment was for ≥6 weeks and ≤4 months, with best response of stable disease or progressive disease"? Return the ori... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:e2ee0466cf340f7e4cb9fe01","quotes":["Patients who had received prior treatment with a PD-1 or PD-L1 inhibitor wer... | [
"CLM:e2ee0466cf340f7e4cb9fe01"
] | [
"PMCID:PMC10151977"
] | [
"SPAN:28060c64c1a704e1bf44cd69",
"SPAN:52019a971ff49ae810a0a044"
] | [] | [] | {"qa_id":"QA:fd63df9d0fb2d6ddd45f7fe7","qa_group_id":"QAG:cf50adaceb8a5235fabbec66","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G008","question":"Which exact source passage supports the statement \"Patients who had received prior PD-1 or PD-L1 therapy were eligibl... |
QA:045769f81a8e54e24ad13736 | QAG:981ca64e14a5ef58fbcbc639 | provenance_qa | exact_evidence_retrieval | provenance_qa | G009 | en | train | Which exact source passage supports the statement "D The co-administration of R-IMPP or PF-0644846 decreased 48 h-IC 50 of simvastatin in KRAS-mutant CRC cells ( left ) ( n = 3)"? Return the original wording with paper, Claim, and Evidence Span references.
Integrated provenance requirements: return the exact supportin... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:a522b9edccca08efcb68ed21","quotes":["D The co-administration of R-IMPP or PF-0644846 reduced 48 h-IC 50 of simvas... | [
"CLM:a522b9edccca08efcb68ed21",
"CLM:125bd56675f6596398baa1a9"
] | [
"PMCID:PMC9270407"
] | [
"SPAN:118bcffdf2a4190475348cbe"
] | [] | [] | {"qa_id":"QA:045769f81a8e54e24ad13736","qa_group_id":"QAG:981ca64e14a5ef58fbcbc639","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G009","question":"Which exact source passage supports the statement \"D The co-administration of R-IMPP or PF-0644846 decreased 48 h-IC ... |
QA:0473ee2343716a81fb73a2b3 | QAG:1301b22e6f18fbabc95f54e6 | provenance_qa | paper_evidence_availability | provenance_qa | G009 | en | train | Does the current traceable evidence dataset contain a usable Claim and exact source span for paper PMCID:PMC8519959? Explicitly abstain if it does not.
Integrated provenance requirements: report evidence availability or insufficiency without inventing missing full text. Keep each subtask answer separately identifiable... | {"answer_type":"integrated_provenance","embedded_answer_types":["paper_evidence_availability"],"exact_evidence_retrieval":null,"limited_evidence_retrieval":null,"paper_evidence_availability":{"answer_type":"explicit_evidence_abstention","paper_id":"PMCID:PMC8519959","verdict":"no_released_traceable_claim","reason":"No ... | [] | [
"PMCID:PMC8519959"
] | [] | [] | [] | {"qa_id":"QA:0473ee2343716a81fb73a2b3","qa_group_id":"QAG:1301b22e6f18fbabc95f54e6","qa_family":"provenance_qa","subtask_type":"paper_evidence_availability","language":"en","cluster_id":"G009","question":"Does the current traceable evidence dataset contain a usable Claim and exact source span for paper PMCID:PMC8519959... |
QA:050664275c65b1db2a0f63f8 | QAG:59e4b74c5ea3e1743fb8143e | provenance_qa | exact_evidence_retrieval | provenance_qa | G009 | en | train | Which exact source passage supports the statement "Indeed, we found that the number of somatic variants was associated with ctDNA amount and residual tumor size in colorectal cancer (Pearson’s correlation, rho = 0.25, p-value = 0.033 and rho = 0.27, p-value = 0.02, respectively), but not in lung cancer ( Supplementary ... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:ffbb2fd708bd476b09a25ae2","quotes":["Indeed, we found that the number of somatic variants were associated with ct... | [
"CLM:ffbb2fd708bd476b09a25ae2",
"CLM:125bd56675f6596398baa1a9"
] | [
"PMCID:PMC8987589"
] | [
"SPAN:aae0df2efa1aa6da12d8a068"
] | [] | [] | {"qa_id":"QA:050664275c65b1db2a0f63f8","qa_group_id":"QAG:59e4b74c5ea3e1743fb8143e","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G009","question":"Which exact source passage supports the statement \"Indeed, we found that the number of somatic variants was associate... |
QA:065acb6678a0d7d236e8ed1e | QAG:cc4fd537d961642b9b9b1949 | provenance_qa | exact_evidence_retrieval | provenance_qa | G009 | en | train | Which exact source passage supports the statement "We recently demonstrated that chemically modified (CM) MIR143#12 inhibited cancer cell growth by targeting KRAS , Son of sevenless homolog 1 ( SOS1 ), AKT , and extracellular signal-regulated kinase ( ERK ) in colorectal cancer, 15 bladder cancer, 16 gastric cancer, 17... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:e7246567d9251cb80586d411","quotes":["We recently demonstrated that chemically modified (CM) MIR143#12 significant... | [
"CLM:e7246567d9251cb80586d411",
"CLM:1cba67a12cdd2f006af7d9e3"
] | [
"PMCID:PMC9507988"
] | [
"SPAN:fa76c2972fcfa0aaad3d10c4"
] | [] | [] | {"qa_id":"QA:065acb6678a0d7d236e8ed1e","qa_group_id":"QAG:cc4fd537d961642b9b9b1949","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G009","question":"Which exact source passage supports the statement \"We recently demonstrated that chemically modified (CM) MIR143#12 i... |
QA:06c4533c01270113002695ea | QAG:391f7a7d44aa5b3ae405daa4 | provenance_qa | exact_evidence_retrieval | provenance_qa | G009 | en | train | Which exact source passage supports the statement "Consistently, PCSK9 inhibitors inhibited p-ERK and cyclin D3 in KRAS-mutant CRC cells (Fig. 4H )"? Return the original wording with paper, Claim, and Evidence Span references.
Integrated provenance requirements: return the exact supporting passage with paper, Claim, a... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:0ced06471fbde63423d72e47","quotes":["Consistently, PCSK9 inhibitors suppressed p-ERK and cyclin D3 in KRAS-mutant... | [
"CLM:0ced06471fbde63423d72e47",
"CLM:125bd56675f6596398baa1a9"
] | [
"PMCID:PMC9270407"
] | [
"SPAN:6850a20e7f2e9875e4e645db"
] | [] | [] | {"qa_id":"QA:06c4533c01270113002695ea","qa_group_id":"QAG:391f7a7d44aa5b3ae405daa4","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G009","question":"Which exact source passage supports the statement \"Consistently, PCSK9 inhibitors inhibited p-ERK and cyclin D3 in KR... |
QA:08ad7b0d81fb282ccde0d8f7 | QAG:da618d9d2581658572f67e90 | provenance_qa | exact_evidence_retrieval | provenance_qa | G009 | en | train | Which exact source passage supports the statement "Pretreatment with RGX-202 decreased pancreatic cancer liver metastatic colonization by fivefold (fig. S1, B and C), demonstrating that depleting cellular creatine/phosphocreatine levels via SLC6A8 inhibition significantly inhibits liver metastasis in a tumor cell–auton... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:1cba67a12cdd2f006af7d9e3","quotes":["Pretreatment with RGX-202 reduced pancreatic cancer liver metastatic coloniz... | [
"CLM:1cba67a12cdd2f006af7d9e3",
"CLM:02548fb255630e1212583b71"
] | [
"PMCID:PMC8494442"
] | [
"SPAN:0bfb1dd999232053dd9445f1"
] | [] | [] | {"qa_id":"QA:08ad7b0d81fb282ccde0d8f7","qa_group_id":"QAG:da618d9d2581658572f67e90","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G009","question":"Which exact source passage supports the statement \"Pretreatment with RGX-202 decreased pancreatic cancer liver metast... |
QA:09306c6d8840391620cabf6e | QAG:ddc78be13bc89b9531731a95 | provenance_qa | exact_evidence_retrieval | provenance_qa | G009 | en | train | Which exact source passage supports the statement "On the other hand, it is demonstrated that inhibition of HSP90 (by shRNA or small molecules) led to a decrease in protein content of STK33 and reduction of viability in vitro and tumor growth rate in vivo for KRAS mutant CRC cell lines ( Azoitei et al., 2012 )"? Return... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:1dc0af8dec685d5b8e3fb7ae","quotes":["On the other hand, it is demonstrated that inhibition of HSP90 (by shRNA or ... | [
"CLM:1dc0af8dec685d5b8e3fb7ae",
"CLM:3cd4082a1fbc3057f3124cf1"
] | [
"PMCID:PMC8696016"
] | [
"SPAN:6085e87f0cce0acaefd9b9f0"
] | [] | [] | {"qa_id":"QA:09306c6d8840391620cabf6e","qa_group_id":"QAG:ddc78be13bc89b9531731a95","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G009","question":"Which exact source passage supports the statement \"On the other hand, it is demonstrated that inhibition of HSP90 (by... |
QA:0bdc8e19215afe0a4da77510 | QAG:9b452a0e54d514ec2c0aadfb | provenance_qa | exact_evidence_retrieval | provenance_qa | G009 | en | train | Which exact source passage supports the statement "BCL2L1 silencing led to marked increases in apoptosis when combined with AZ’1569 in all KRAS G12C MT colorectal cancer models, compared with the effects of each treatment alone"? Return the original wording with paper, Claim, and Evidence Span references.
Integrated p... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:93f9b75066f15a8249178516","quotes":["BCL2L1 silencing resulted in marked increases in apoptosis when combined wit... | [
"CLM:93f9b75066f15a8249178516",
"CLM:1cba67a12cdd2f006af7d9e3"
] | [
"PMCID:PMC9808374"
] | [
"SPAN:ad873bbe4e37bd90cc2ba23e"
] | [] | [] | {"qa_id":"QA:0bdc8e19215afe0a4da77510","qa_group_id":"QAG:9b452a0e54d514ec2c0aadfb","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G009","question":"Which exact source passage supports the statement \"BCL2L1 silencing led to marked increases in apoptosis when combine... |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.